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ABSTRACT 
Diabetes is rapidly increasing worldwide, and the number of patients suffering 
from diabetes is projected to rise with 50 % over the next 25 years, then affecting 
almost 600 million adults. Type 2 diabetes comprises 90-95 % of all people with 
diabetes, and they constitute a patient group that carries a high burden of 
cardiovascular disease. Patients with type 2 diabetes suffer a 2-4 times higher risk for 
myocardial infarction and stroke than healthy persons. In addition to this, diabetic 
patients have an increased atherosclerotic burden. Endothelial dysfunction is thought 
to be an early and important predictor of atherosclerosis and cardiovascular disease, 
and in people with type 2 diabetes endothelial dysfunction is a common finding. Also, 
diabetic patients have an increased risk of restenosis and late stent thrombosis upon 
surgical intervention to treat atherosclerosis, complications that are related to a 
defective re-growth of the endothelial cells. The relationship between hyperglycemia 
and macrovascular complications is still uncertain, at least in terms of the possibility of 
reducing cardiovascular events solely by improving glycemic control. The importance 
of finding other strategies to improve cardiovascular outcome in type 2 diabetes 
patients has consequently emerged. My aim with this thesis has therefore been to 
investigate how agents used for type 2 diabetes management directly affect the 
vasculature under normal and simulated diabetic conditions.  
We studied the effect of antidiabetic agents on endothelial cell viability, 
regeneration and apoptosis in three in vitro studies. We found that a number of 
agents could induce proliferation under normal and hyperglycemic conditions, and 
protect endothelial cells from free fatty acid-induced apoptosis. We studied two 
antihyperglycemic agents’, metformin and exendin-4, lipoprotective effects in more 
detail. We found that exendin-4 and metformin protected endothelial cells against 
lipoapoptosis by modulating pro-apoptotic kinases. Exendin-4 and metformin were 
also able to activate intracellular survival pathways and to improve endothelial nitric 
oxide synthase dysfunction. In our last study, we investigated the effect of exendin-4 
on endothelial cells and smooth muscle cells in vivo by using a rat model of vascular 
injury, where the endothelium is denuded in the carotid artery; we found that 
exendin-4 selectively targeted the smooth muscle cells and decreased the injury-
induced intimal hyperplasia. Treatment with exendin-4 did not affect the re-growth of 
the endothelial cells, but on the other hand improved arterial wall elasticity, 
suggesting that the re-grown endothelial cells were better functioning in exendin-4-
treated animals.  
In conclusion, we show that drugs used in the management of type 2 diabetes 
exert direct positive effects on the vasculature. This might be of clinical benefit for 
patients suffering from diabetes by limiting the adverse consequences of the 
macrovascular complications of type 2 diabetes, as dysfunction of endothelial cells 
and smooth muscle cells is believed to contribute to premature development of 
atherosclerosis. Our findings might also be of therapeutic benefit for diabetic patients 
undergoing revascularization to treat atherosclerosis, since restenosis and late stent 
thrombosis are overrepresented and serious complications among these patients. 
  
SVENSK SAMMANFATTNING 
Antalet personer som lider av diabetes ökar snabbt världen över och 
prevalensen av diabetes är beräknad att öka med 50 % under de nästkommande 25 
åren och kommer då att drabba ungefär 600 miljoner vuxna. Personer med typ 2 
diabetes utgör 90-95 % av det totala antalet diabetiker i världen och de är en 
patientgrupp med en förhöjd risk för att utveckla hjärt- och kärlsjukdomar. Jämfört 
med en frisk person så har en typ 2 diabetiker en 2-4 gånger högre risk att insjukna i 
hjärtinfarkt eller stroke, dessutom har diabetespatienter även en ökad börda av 
ateroskleros. Endoteldysfunktion tros vara en tidig indikator för utvecklandet av 
ateroskleros samt kardiovaskulär sjukdom och endoteldysfunktion ses ofta hos typ 2 
diabetes patienter. Därutöver så är det vanligare att diabetiker dabbas av 
komplikationer så som återförträngning av kärlet och trombos efter kirurgiska 
interventioner riktade mot att behandla åderförkalkning. Dessa komplikationer är 
associerade till en defekt återväxt av endotelcellerna. Om ett förhållande finns mellan 
hyperglykemi och makrovaskulära komplikationer är inte helt klarlagt, åtminstone när 
det gäller möjligheten att minska risken för kardiovaskulära händelser enbart genom 
att förbättra den glykemiska kontrollen. Därför är det viktigt att hitta andra strategier 
för att minska uppkomsten av kardiovaskulära komplikationer hos typ 2-
diabetespatienter. Syftet med denna avhandling har därför varit att undersöka hur 
läkemedel som används inom behandlingsramen för typ 2-diabetes direkt påverkar 
cellerna i våra kärl under normala och simulerade diabetiska förhållanden.   
Vi studerade effekten av antidiabetiska läkemedel på endotelcells viabilitet, 
regeneration och celldöd in vitro i tre delstudier. Vi fann att ett antal läkemedel 
positivt påverkade celldelningen av endotelceller vilka var exponerade för både 
normal och hög sockernivå, samt skyddade endotelceller från celldöd inducerad av en 
mättad fettsyra. Vi undersökte även de två antidiabetiska substanserna exendin-4 och 
metformin lite närmare och från dessa studier så drog vi slutsatsen att de båda 
skyddade endotelceller från fettsyreinducerad celldöd genom att minska aktiviteten 
av proapoptotiska proteinkinaser. Exendin-4 och metformin aktiverade även 
skyddande cellsignaleringsvägar och förbättrade funktionen av endotelcellernas 
kväveoxidsyntas. I vår fjärde delstudie utredde vi effekten av exendin-4 på endotel- 
och glattmuskelceller in vivo vid kärlskada med hjälp av en råttmodell där endotelet 
skrapas bort i karotisartären. Våra fynd visade att exendin-4 selektivt påverkar 
glattmuskelceller samt minskade tillväxten av intiman. Behandling med exendin-4 
påverkade inte återväxten av endotelcellerna, men däremot förbättrades elasticiteten 
i kärlväggen, vilket kan tyda på att exenidin-4 behandling genererar mer 
välfungerande endotelceller. 
För att summera, vi visar i denna avhandling att läkemedel som används i 
behandlingen av typ 2-diabetes utövar positiva effekter på kärlsystemet. Detta kan 
vara till klinisk nytta för patienter som lider av diabetes då det kan bidra till att 
begränsa konsekvenserna av de kardiovaskulära komplikationerna vid typ 2-diabetes, 
eftersom dysfunktion av endotelceller tros bidra till en prematur utveckling av 
ateroskleros. Våra resultat kan också vara av terapeutisk nytta för diabetespatienter 
som genomgår revaskularisering i syfte att behandla åderförkalkning, eftersom 
potentiellt dödliga komplikationer såsom förträngning och trombos är 
överrepresenterade inom denna patientgrupp. 
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1 INTRODUCTION 
 
1.1 DIABETES 
Diabetes  mellitus is a heterogeneous and complex group of disorders, characterized 
by hyperglycemia [1]. According to the World Health Organization (WHO) is diabetes 
diagnosed if the fasting plasma glucose is > 7 mmol/l on two different occasions or if 
the plasma glucose concentration is > 11.1 mmol/l two hours following an oral glucose 
tolerance test [2]. The American Diabetes Association (ADA) divides diabetes into four 
different categories based on etiology and clinical features: 1) Type 1 diabetes mellitus 
(T1DM), which manifests with insulin deficiency due to β-cell destruction. 2) Type 2 
diabetes mellitus (T2DM), characterized by a progressive insulin secretory defect and 
insulin resistance. 3) Gestational diabetes, diagnosed during pregnancy, and 4) other 
specific types of diabetes, which might be due to genetic defects in β-cell function or 
insulin action, disease in the exocrine pancreas, or induced by drugs- or chemicals [3].  
 
Diabetes is rapidly increasing worldwide, and it is estimated that 382 million adults 
suffer from the disease today, a number that is projected to rise with more than 50 % 
in less than 25 years, affecting then almost 600 million adults [4]. The global health 
expenditure in order to treat diabetes and its complications was estimated to 548 
billion US dollars during 2013. However, there are substantial differences between 
countries and regions on the health spending for treating diabetes. This is clearly 
emphasized by the fact that 80 % of all people with diabetes lives in low- and middle 
income countries, but only 20 % of the global health expenditure for treatment of 
diabetes was spent here last year [4].   
 
1.1.1 Type 2 diabetes 
T2DM comprises 90- 95 % of all people with diabetes. It is a heterogeneous disorder 
but characteristic features are peripheral insulin resistance and a relative insulin 
deficiency due to impaired β-cell function, which eventually leads to fasting 
hyperglycemia, and overt T2DM [1, 3]. Although the etiology of the disease is not 
completely known, T2DM is associated with risk factors such as obesity, physical 
inactivity, family history of diabetes, advancing age, hypertension, dyslipidemia, prior 
gestational diabetes, and is more frequently seen in certain ethnicities [3, 4]. The 
disease might go unnoticed for several years since glycemia gradually increases, and it 
is often not diagnosed until complications due to the disease have already developed. 
Clinical management of T2DM consists of a combination of lifestyle interventions with 
changes in diet and physical activity, addition of one or more anti-diabetic agent, and 
if the glycemia is poorly controlled, eventually also insulin injections [3, 4]. The 
increase in T2DM is not only contained in the adult population; at the same time as 
childhood obesity is increasing, T2DM emerges as a new form of pediatric diabetes. 
T2DM was in the past rarely seen in young individuals (under 20 years of age), and all 
diabetic children were then assumed to suffer from T1DM. Today, however, studies 
from both China [5] and the U.S. [6] show that the prevalence of T2DM is rapidly 
increasing and in some ethnic groups the incidence of T2DM in young people has 
already surpassed that of T1DM [7, 8].  
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1.1.2 The metabolic syndrome 
The metabolic syndrome refers to a clustering of cardiovascular risk factors, and it was 
first defined by Reaven in 1988 [9]. After this the WHO, the International Diabetes 
Federation and others have come up with their own criteria of the metabolic 
syndrome. There is not yet a consensus definition in place, making it hard to compare 
between studies and to identify individuals at risk. This has generated criticism from 
the European Association for the Study of Diabetes (EASD) and the ADA, which -- in a 
joint statement in 2005 -- suggested that the term “metabolic syndrome” should be 
carefully used until its status as a “syndrome” has been verified with more research 
[10]. However, the risk factors that are most commonly mentioned when discussing 
the metabolic syndrome are insulin resistance (impaired response of peripheral 
tissues to insulin [11]) or impaired fasting glucose, obesity (BMI or waist 
circumference), dyslipidemia (abnormal levels of triglycerides and/or HDL cholesterol) 
and hypertension. If an individual has three or more of these risk factors, he or she is 
considered to have the metabolic syndrome and thus an 1.5-3 fold increased risk of 
cardiovascular disease and five times higher risk to develop T2DM over the next five 
to ten years [12, 13]. As a matter of fact, insulin resistance per se is an independent 
risk factor for developing cardiovascular disease [14, 15]. 
 
1.1.3 Complications of diabetes 
Diabetes is a leading cause of cardiovascular disease, blindness, kidney failure, and 
lower-limb amputation, in almost all high-income countries. This trend will probably 
be followed by low- and middle-income countries as the prevalence of diabetes 
increases worldwide [4]. Although microvascular complications are the most common 
cause of morbidity in diabetic patients, it is the macrovascular complications that 
account for  the most common cause of mortality, where myocardial infarction (MI) 
and stroke account for ~ 80 % of all deaths [15]. In individuals with T2DM, the etiology 
for up to 75 % of the mortality is atherosclerotic cardiovascular disease [16]. In T1DM, 
hyperglycemia seems to be more important for the development of both micro-and 
macrovascular complications than in T2DM, where the picture is more complex [17].  
 
1.1.3.1 Microvascular complications 
Diabetic retinopathy is probably the most common complication of diabetes, and the 
strongest predictor for the disease is the duration of diabetes. It is caused by 
hyperglycemia in combination with hypertension and dyslipidemia. Diabetic 
retinopathy is the leading cause of blindness in the adult population between 20-74 
years of age [1, 18].  
 
Diabetic nephropathy is seen in 20-40 % of the diabetic patients and it is the leading 
cause of chronic kidney disease needing dialysis or kidney transplantation in the U.S. 
[18]. Like other diabetic microvascular complications, there is a strong association 
between glucose control and the risk of developing diabetic nephropathy. This 
condition is associated with changes in glomeruli and when the nephropathy is fully 
developed it is characterized by Kimmelstiel–Wilson nodules. These lesions are not 
seen in any other kidney disease, suggesting that they are specifically caused by 
chronic hyperglycemia seen in diabetic patients. When these changes are established, 
several other factors can affect the clinical outcome, especially blood pressure [19].  
   3 
 
Hyperglycemia in combination with high blood pressure can lead to damage of the 
nerves (neuropathy), with the feet being most commonly affected. Neuropathies are 
heterogeneous and with diverse clinical manifestations. Neuropathies are common 
late complications of diabetes, and patients often experience pain, a tingling feeling 
and numbness. Numbness might complicate things further since wounds might go 
unnoticed, leading to foot deformations, ulcerations and infections, which in a worst 
case scenario lead to amputation [1, 4, 18]. The overall risk of amputation is 40 times 
higher in diabetics than in non-diabetic patients [1] 
 
1.1.3.2 Macrovascular complications 
Patients with T2DM suffer an increased risk for MI and stroke, a risk that is equal to 
patients who have already suffered a previous MI and 2-4 times higher than a person 
without a previous MI or T2DM [20]. In addition to this, diabetic patients have an 
increased atherosclerotic burden which can cause obstruction of arteries, and not only 
in the coronary circulation. Also the more peripheral arteries are affected, which can 
lead to vascular occlusion in the extremities, known as peripheral artery disease 
(PAD). The occlusions might cause symptoms such as pain, and cramping in the legs, 
due to the ischemia and lactic acid build up. PAD is a marker for systemic vascular 
disease and a major risk factor for lower extremity amputation [21].  
 
In general, microvascular complications are caused by prolonged exposure to 
hyperglycemia, and the link between intensified glucose control and reduced 
complications is well supported in numerous studies for T1DM (DCCT and SDIS) and 
for T2DM (UKPDS, ACCORD, ADVANCE, VADT). This is in contrast to hyperglycemia and 
macrovascular complications, where the relationship is still uncertain, at least in terms 
of the possibility of reducing cardiovascular events solely by improving glycemic 
control [22-28]. The only randomized controlled trial that so far has been able to 
decrease macrovascular events and mortality within the trial period, is the STENO-2 
study. Here the intervention protocol targeted all known cardiovascular risk factors, 
such as hyperglycemia, hypertension, dyslipidemia, overweight, physical inactivity, 
smoking and diet [29, 30]. On the other hand, the UKPDS (T2DM) and DCCT/EDIC 
(T1DM) studies did show a significant reduction of macrovascular complications in the 
post-trial period, even though the glycemic differences were lost [31, 32], and in 
speculation this was termed a “legacy effect”. However, since there is no clear cut 
association between hyperglycemia and macrovascular complications, it is of interest 
to consider whether and how drugs used against diabetes directly affect the 
vasculature. 
 
1.2 THE VASCULATURE 
1.2.1 Overview 
Blood vessels can be divided into five different groups: 1) the arteries, thick-walled 
vessels which carry the blood away from the heart. 2) The arterioles are smaller 
branches of the arteries with muscular walls that deliver blood into 3) the capillaries. 
The capillaries are small and their vessel walls consist of only one cell layer in order to 
allow for efficacious exchange of molecules between the blood and tissues and 
between blood and air in the lung tissue. The capillaries then unite and form 4) 
 4 
venules, that have a slightly thicker vessel wall and begin the transport of the blood 
back to the heart. Venules then merge and form larger vessels, viz. 5) the veins, which 
continue the transport of blood until it is returned to the heart [33, 34].  
 
The macrovessels (arteries, arterioles and veins) are made up of three layers (tunics), 
separated by elastic membranes (depicted in figure 1). The innermost tunica, the 
intima, is a single layer of endothelial cells lining the internal lumen of the vessel. The 
media, the thickest layer, which constitutes of smooth muscle cells, and the 
outermost membrane, the adventitia, made up of supportive connective tissue, mast 
cells, fibroblasts, nerve endings and microvessels (vasa vasorum) [33-35].  
 
 
 
 
Figure 1. Cross section of the rat common carotid artery. The common carotid artery has 
been stained with Masson Trichrome, where blue staining represents collagen, red represents 
muscle and, hematoxylin staining identifies the nuclei.  
 
1.2.2 Endothelial cells 
The endothelial cells constitute the endothelium, a single-cell inner lining of blood 
vessels, which is situated as a barrier between the circulating blood and the vascular 
smooth muscle cells. The endothelium is the main regulator of vascular wall 
homeostasis by controlling the vascular permeability of constituents in plasma. It also 
protects the vessels from activation of clotting and proinflammatory factors by 
regulating platelet and leukocyte adhesion. Additionally, it participates in the 
regulation of vascular tone, blood flow and blood pressure by releasing vasodilating 
mediators such as nitric oxide (NO), endothelial derived hyperpolarizing factor (EDHF), 
and prostacyclin (PGI2), and vasoconstrictors such as endothelin-1 (ET-1) and 
angiotensin-II [36, 37].  
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1.2.2.1 Endothelial nitric oxide synthase and nitric oxide production 
The most potent vasodilator in the body is NO, which is synthesized when L-arginine is 
converted into L- citrulline by the enzyme nitric oxide synthase (NOS). There are 
several different isoforms of NOS, although all are homologous. The NOS family can be 
divided into two different categories, the constitutive and the inducible NOS, which 
differ in their activities and regulation. The constitutive category includes neuronal 
NOS (also known as NOS I) and endothelial NOS (also known as NOS III), which are 
abundantly expressed. These isoforms are regulated by the calcium-binding protein 
calmodulin (CaM), which means that they are inactive until the intracellular level of 
calcium rises and forms a complex with CaM. The calcium-CaM complex then binds to 
NOS, resulting in its activation. Inducible NOS (also known as NOS II) is CaM-
independent. Its expression is dependent on inflammatory cytokines and upon 
activation inducible NOS produces up to a thousand times more NO than endothelial 
NOS (eNOS) [38, 39].  
 
The vascular tone is controlled by eNOS producing NO in response to several stimuli, 
e.g. insulin, shear stress, bradykinin and acetylcholine [36]. eNOS activity is 
determined by several cofactors, such as tetrahydrobiopterin (BH4), nicotinamide 
adenine dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD) and flavin 
mononucleotide (FMN), for its function [40]. Upon production diffuses NO from the 
endothelial cells to the smooth muscle cells (SMC), where it activates soluble guanylyl 
cyclase, resulting in the production of cyclic GMP (cGMP). cGMP activates a cGMP-
dependent protein kinase (PKG). This leads to an increased displacement of calcium in 
the cytosol, which inhibitits the contractile machinery in SMCs, causing them to relax 
thus dilating the vessel [41]. In addition to this, NO plays an essential role in the 
regulation of endothelial function [42] and has been shown to be involved in 
endothelial cell growth, migration, apoptosis and angiogenesis [43-45]. Recently, an 
alternative pathway for NO formation in mammals have been described, involving the 
reduction of inorganic nitrate, which was long believed to merely be an undesired 
dietary constituent and an inert product formed upon oxidation of NO, to nitrite 
which can be further reduced to NO. This pathway works in parallel to the oxygen-
dependent classical pathway described above, but -- more importantly -- when oxygen 
availability and NOS activity are reduced, e.g. during an ischemic event, nitrite 
reduction to NO becomes more pronounced. This pathway can therefore be viewed as 
a back‑up system to ensure that there is sufficient NO formation even when oxygen 
supply is limited [46].  
 
1.2.3 Smooth muscle cells 
SMCs reside underneath the endothelium, and are under normal circumstances 
maintained in a differentiated contractile state. Their principal function is contraction 
and regulation of blood vessel diameter, maintenance of blood pressure, and blood 
flow distribution [47]. SMCs have low turnover in their differentiated state, which is 
also controlled by the endothelial cells through their production of NO. NO is well-
known to inhibit SMC proliferation and migration [48]. However, SMCs can 
dedifferentiate into a synthetic phenotype and then exhibit high rates of proliferation, 
migration and production of extra-cellular matrix components. The conversion of 
SMCs to a synthetic phenotype is an early event in many cardiovascular diseases, such 
as atherosclerosis, restenosis and abdominal aortic aneurysm. Intriguingly, it has been 
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suggested, due to the increased risk for cardiovascular complications in T2DM, that a 
“diabetic phenotype” of SMCs may exist, and that hyperglycemia and 
hyperinsulinemia might have direct effects also on the SMCs in the vessel wall [49].     
 
1.3 ATHEROSCLEROSIS 
Atherosclerosis is a chronic, multifactorial and progressive disease that begins to 
develop already during adolescence [50]. It is typified by lesions, called plaques, in the 
arteries that are characterized by a fibrotic cap, inflammation, infiltration of immune 
cells, lipid accumulation initiating a lipid-rich core, cell death and fibrosis. However, 
the disease might not become clinically manifest until a plaque ruptures causing a 
thrombosis, which is the most common cause of coronary artery and cerebrovascular 
ischemic disease [51, 52].  
 
1.3.1 The development of an atherosclerotic plaque 
As described above, the arterial endothelium normally regulates the homeostasis; but, 
in response to certain circumstances and factors, i.e. turbulent blood flow, oxidized 
low-density lipoprotein (oxLDL), or pro-inflammatory mediators the endothelium 
becomes activated and more permeable, allowing entry and retention of cholesterol-
rich LDL. Activated endothelial cells express leukocyte adhesion molecules that 
capture leukocytes (monocytes and T cells) in the circulation, which migrate into the 
artery wall. At the same time, endothelial cells secrete chemokines to attract 
monocytes, dendritic cells and T cells to the intima. Following this, monocytes in the 
intima are exposed to macrophage colony-stimulating factor produced by endothelial 
cells causing monocytes to differentiate into macrophages. Macrophages express 
scavenger receptors causing uptake of oxLDL; this cholesterol accumulation eventually 
turns the macrophages into foam cells [52].  
 
As the lesion progresses, SMCs from the media migrate into the intima where they 
proliferate, produce extracellular matrix molecules and form a fibrous cap that covers 
the plaque. Underneath the cap reside numerous foam cells, of which some die and 
release their lipids. When the dead cells are not properly cleared away, accumulation 
of cellular debris and extracellular lipids is promoted, forming a lipid rich necrotic core. 
Clinical manifestations of atherosclerosis occur either through expansion of the lesion, 
which causes narrowing of the lumen, thus reducing the blood flow; or as a thrombus 
caused by plaque rupture, leading to rapid and complete obstruction of the vessel.  
Lesions that rupture are not necessarily the most obstructive ones; common 
characteristics of ruptured plaques are thin fibrous caps, and that they contain few 
SMCs but many macrophages. The infiltrating inflammatory cells within the plaque 
cause amplification of enzymes that degrade collagen and generate mediators 
triggering SMC death. Macrophages within the plaque also produce pro-coagulant 
tissue factor rendering the core thrombogenic [35] (figure 2).  
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Figure 2. The development of an atherosclerotic plaque and the cellular processes involved. 
Reproduced with permission from Watkins, H. et al. Nat Rev Genet. 2006 Mar;7(3):163-73, Copyright 
©Nature Publishing Group. 
 
1.3.2 Endothelial dysfunction in diabetes 
Endothelial dysfunction is characterized by an imbalance between vasodilating 
factors, vasoconstrictors, antithrombotic and prothrombotic factors, predisposing the 
endothelium to an atherogenic milieu [53]. When normal vascular endothelial 
function fails, it will change into a more activated phenotype which mediates adhesion 
of monocytes and platelets, increased synthesis of pro-inflammatory and pro-
thrombotic factors, inflammation, trans-endothelial transport of LDL, increased 
oxidative stress, and inappropriate vasoconstriction or vasodilation [37, 42]. 
Endothelial dysfunction has been observed in T1DM, T2DM, in obesity, hypertension, 
smoking, and in patients with insulin resistance. The extent of endothelium-
dependent vasodilation correlates in obese and insulin resistant subjects with their 
individual insulin sensitivity [42]. Endothelial dysfunction has thus emerged as an 
important early target for preventing atherosclerosis and cardiovascular disease [42, 
54].  
 
Pathological conditions such as hyperglycemia, hyperlipidemia, and inflammation, 
oftentimes seen in diabetic patients, might trigger superoxide (O2.-) production, 
through activation of the NADPH oxidase [42, 55]. Superoxide quickly reacts with NO 
forming the very potent oxidizing species peroxynitrite (ONOO-), which may oxidize 
the essential eNOS cofactor BH4 or destabilize the eNOS dimer, causing uncoupling of 
eNOS. Uncoupled eNOS produces superoxide instead of NO, thus further enhancing 
the oxidative stress and decreasing NO bioavailability [55, 56]. Endothelial dysfunction 
is coupled to a decrease in NO, either by reduced synthesis or decreased 
bioavailability [57]. It has also been shown that bioavailability of NO is reduced in 
patients with T2DM [58, 59] affecting their endothelial-dependent vasodilation. 
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1.3.2.1 Glucotoxicity of endothelial cells 
In diabetic patients, every cell in the body is exposed to abnormally high glucose 
concentrations; however, not all of them are adversely impacted by hyperglycemia. 
Endothelial cells are particularly susceptible to glucose-induced damage, probably 
because they express the glucose transporter (GLUT)-1 -- which is not sensitive to 
insulin -- which means that they cannot downregulate their glucose uptake when 
glycemia increases [60]. Hyperglycemia potentially promotes atherosclerosis by 
inducing many changes in the vascular tissue. The underlying mechanisms that have 
emerged map most of the pathological alterations seen in the vasculature of diabetic 
humans and animals. 1) Advanced glycosylation end products (AGEs) are formed by 
the non-enzymatic glycosylation of proteins. These modified intracellular proteins and 
extra cellular matrix components have an altered function and interact abnormally 
with other matrix components and matrix receptors, respectively. Also, plasma 
proteins that are modified with AGEs interact with the AGE receptor (RAGE) on 
vascular cells, which induces the production of reactive oxygen species (ROS) and 
subsequent activation of the transcription factor nuclear factor (NF)-B, causing 
pathological changes in gene expression [61, 62]. 2) Hyperglycemia can also cause de 
novo synthesis of diacylglycerol (DAG), which activates protein kinase C (PKC). 
Activation of PKC might downstream lead to blood flow abnormalities, increased 
permeability of the endothelium, activation of the pro-inflammatory NF-B, and 
oxidative stress by activation of NADPH oxidase. It may also cause thickening of the 
basement membrane in capillaries and over-expression of the fibrinolytic inhibitor, 
plasminogen activator inhibitor -1 (PAI-1), causing the vessel to be more susceptible to 
vascular occlusion [61, 62]. 3) Hyperglycemia increases flux through the hexosamine 
pathway, which affects the activity of various enzymes, and of particular importance 
eNOS. Specific metabolites in this pathway have been demonstrated to bind to the Akt 
activation site of eNOS, thus inhibiting its activation [61, 63]. 4) Hyperglycemia also 
augments oxidative stress by increasing the flux through the polyol pathway, causing  
a depletion of NADPH, an important co-factor for the antioxidant glutathione 
reductase [64]. The above mentioned theories have all emerged to explain the 
unfavorable effects of hyperglycemia on the endothelium; however, they were lacking 
a common element linking them together. A unifying hypothesis was therefore put 
forth by Brownlee in 2001 suggesting that oxidative stress, caused by overproduction 
of superoxide in the mitochondrial respiratory chain, is the common denominator 
upstream of these events [65].  
 
1.3.2.2 Lipotoxicity of endothelial cells 
Increased circulating free fatty acids (FFAs) are oftentimes seen in patients with T2DM 
[66]. FFAs, formed during lipolysis from triglycerides, are known to impair the 
endothelial-dependent vasodilatation in humans, and to decrease the bioavailability 
of endogenous NO resulting in impaired endothelial function [67]. One possible 
explanation for this is that FFAs have been shown to cause de novo synthesis of 
ceramides, which induce protein phosphatase 2A to co-localize with eNOS, leading to 
a reduced agonist-stimulated eNOS phosphorylation and NO production in endothelial 
cells [68]. FFAs have also been shown to activate IKK-β, a regulator of NF-B. Upon 
activation impairs IKK-β insulin dependent insulin receptor substrate-1 (IRS-1), Akt and 
eNOS phosphorylation, and reduces NO production, probably by directly interfering 
with IRS-1 activity downstream of the insulin receptor [69]. As with hyperglycemia, 
   9 
excess FFAs can also cause de novo synthesis of DAG that activates PKC, contributing 
to endothelial damage as described above. Elevated levels of FFAs might also cause 
lipid accumulation within endothelial cells; this can modulate membrane fluidity, 
proteoglycan metabolism and signal transduction [70]. In addition, increased levels of 
FFAs induce ROS, endoplasmic reticulum (ER) stress and apoptosis of endothelial cells, 
events that are supposed to be involved in, and contribute to, endothelial dysfunction, 
inflammation and atherosclerosis [71-73].   
 
1.3.2.3 Oxidative stress 
Diabetes is linked to oxidative stress. Oxidative stress occurs when there is an 
imbalance between oxidant production and the cellular antioxidant defense system. 
Oxidative stress, through ROS generation, causes oxidative damage to DNA, proteins 
and lipids [74]. One of the mechanism by which hyperglycemia and FFAs can induce 
oxidative stress appears to be through overproduction of the superoxide anion via PKC 
dependent activation of the NADPH oxidase [75]. Superoxide can in itself cause 
damage to cells, and as mentioned above, it might react with NO thus forming 
peroxynitrite [74]. Peroxynitrite might not only contribute to oxidative stress through 
oxidation of BH4, but it can also oxidize other small-molecule antioxidants such as 
glutathione and cysteine. Apart from this, peroxynitrite can inactivate antioxidant 
enzymes, such as glutathione reductase, glutaredoxin and superoxide dismutase, as 
well as dimethylarginine dimethylaminohydrolase, which metabolizes the endogenous 
inhibitor of eNOS, asymmetric dimethylarginine (ADMA), thus further adding to the 
oxidative stress [76]. Another mechanism by which hyperglycemia and FFAs might 
induce oxidative stress is by overloading the mitochondrial respiratory chain due to 
excess electron donors (NADH, FADH2) generated during the citric acid cycle. This may 
lead to leakage of electrons, which spontaneously form superoxide in the aerobic 
environment by reacting with oxygen, thereby increasing mitochondrial ROS 
production [56, 74].  
 
An interesting hypothesis was recently put forth on the topic of oxidative stress and 
T2DM [77]. Contrary to the negative effects usually attributed to ROS formation, the 
author (the Nobel laureate James D Watson) suggests that an oxidative environment 
is needed for promoting the action of insulin. He speculates that ROS is necessary for 
proper folding of proteins, by providing a sufficient oxidative redox potential for 
formation of disulphide bonds in the ER. Without the correct folding, proteins will stay 
in the ER, initiating the unfolded protein response. He further alludes that antioxidants 
and metformin (due to its antioxidant effect) might lower the endogenous ROS levels 
below what is needed for proper disulphide bond formation, therefore abrogating the 
positive effect of exercise-induced ROS formation. This might then be the explanation 
of why antioxidant supplementation and metformin have been reported to prevent 
increased insulin sensitivity following physical activity [77-79].  
 
1.3.3 Atherosclerosis and diabetes 
It is generally agreed that people suffering from diabetes have approximately a two-
fold increased risk of vascular disease, independent of other risk factors [80]. Patients 
with T2DM also have a greater plaque burden, a higher number of healed plaque 
ruptures and a larger necrotic core, compared to non-diabetic subjects [81]. Another 
study, systematically analyzing patients having undergone intravascular ultrasound, 
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showed that diabetic subjects had a greater burden of coronary atherosclerosis, an 
impaired compensatory remodeling of the vessel wall in order to accommodate the 
greater atherosclerotic burden and that the plaque progression was also more rapid, 
despite the use of established medical therapies, than their non-diabetic counterparts 
[82]. Why diabetic patients have a higher burden of atherosclerosis has not been fully 
elucidated. Oxidative stress is generally considered as a pathogenic mechanism for 
atherosclerosis. It is also considered to be one potential mechanism for the 
accelerated atherosclerosis observed in and associated with the metabolic syndrome, 
insulin resistance, prediabetes, and T2DM [62, 83]. Insulin per se and insulin resistance 
are also potential culprits in the atherosclerosis development seen in T2DM. Both in 
vivo and in vitro studies have shown that insulin, especially at high doses, promotes 
atherogenesis. Insulin resistance abrogates signaling through the insulin receptor, 
which impairs NO production, causing endothelial dysfunction and thus accelerating 
the atherosclerotic process [15]. Additionally, in insulin resistance there is a 
disproportionate increase in proinsulin, which has been reported to be associated 
with adverse cardiovascular effects [84, 85].  
 
1.3.4 Interventions used to treat symptomatic atherosclerosis 
Revascularization for patients with coronary artery disease is routinely performed 
throughout the world; percutaneous coronary intervention (PCI) being a commonly 
used procedure. With angioplasty, the narrowed or closed off vessel is reopened, 
using a thin catheter with a small inflatable balloon at the end. When in place, the 
balloon is inflated at the site of the lesion to compress the plaque against the artery 
wall, thus restoring blood flow. In order to increase the chances of keeping the vessel 
open a metal mesh tube, a stent, is often inserted into the lumen at the site of the 
lesion [86].  
 
A successful revascularization in T2DM is in 25-30 % of the cases complicated by 
restenosis [87], which is a re-narrowing of the previously dilated vessel segment, and 
if the patient experiences symptoms a repeat revascularization is needed (figure 3). 
Restenosis usually reaches is maximum within the first 6-12 months after the 
procedure [88]. Restenosis is caused by vascular remodeling and formation of intimal 
hyperplasia, a vessel wall healing response involving migration and proliferation of 
SMCs in the intima, which leads to a re-narrowing of the lumen at the initial 
intervention site [89]. The process is also accelerated due to the loss of the 
endothelium, which normally cover the SMCs and inhibits their proliferation and 
migration [48]. The use of drug-eluting stents (DES) has reduced restenosis rates 
significantly. However, the re-intervention rate in diabetics with DES is around twice 
as frequent as that in patients without diabetes [90, 91]. Also, the risk of late in-stent 
thrombosis associated with DES is increased in diabetic patients [92-95]. The 
mechanism behind this phenomenon is not completely known, but a defective re-
endothelialization, due to the non-selective anti-proliferative effect of the agent that 
is released from the stent, is suggested to be a common denominator for these cases 
[96]. 
 
Coronary artery bypass grafting (CABG) is another revascularization procedure in 
which a healthy vessel, harvested from another part of the body, is connected to the 
blocked coronary artery, the grafted vessel bypasses the lesion thus restoring blood 
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flow.  It has been discussed whether or not diabetic patients benefit better from CABG 
than PCI with DES, a randomized controlled trial (the FREEDOM trial) specifically 
designed to compare these two methods has recently been published. Diabetics and 
patients with multivessel disease displayed a significantly reduced risk of all-cause 
mortality and myocardial infarction but a higher risk of stroke after undergoing CABG 
compared to PCI with DES [97].   
 
 
 
Figure 3. Restenosis after percutaneous transluminal coronary angioplasty (PTCA) a.k.a PCI and 
coronary stenting. Reproduced with permission from Bittl JA. N Engl J Med 1996;335:1290-1302, 
Copyright ©Massachusetts Medical Society. 
 
1.4 GLUCAGON LIKE PEPTIDE-1 
The concept that certain factors in the gut could influence glycemia was first 
postulated in the early 1900’s [98, 99], and in 1932 Jean La Barre introduced the term 
“incretin”, in order to describe these glucose-lowering, intestinal-derived factors 
[100]. In the mid 1960’s, the methodology to measure insulin had improved and it 
could then be shown that an oral ingestion of glucose generates a higher increase in 
plasma insulin, when compared to intravenous infusion of an equal amount of 
glucose, again suggesting that gut-derived factors must be involved [101, 102]. This 
phenomenon was later termed “the incretin effect”, and is estimated to be 
responsible for 20 to 60 % of the postprandial insulin secretion in healthy individuals 
[100, 103, 104]. Glucose-dependent insulinotropic polypeptide (GIP) was the first 
incretin to be identified in the 1970’s; however, removal of GIP attenuated, but did 
not eliminate, the incretin effect, providing circumstantial evidence for the existence 
of another incretin. In the 1980’s a second peptide was cloned and sequenced from 
the glucagon gene, viz. glucagon-like peptide-1 (GLP-1) [105], which was later shown 
to potentiate insulin secretion in both preclinical [106] and clinical studies [107, 108]. 
GLP-1 is produced and secreted from the enteroendocrine L-cells in the small and 
large intestine and is formed after posttranslational processing of proglucagon by 
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prohormone convertase 1/3 [109]. GLP-1 is released into the circulation in two 
equipotent forms, GLP-1(7-37) and GLP-1(7-36)amide, with GLP-1(7-36)amide being 
the most abundant in the circulation after a meal. Circulating plasma levels of GLP-1 
range between 5-10 pmol/L in the fasted state but increases rapidly after a meal, 
reaching 15-50 pmol/L [110]. After its release, circulating GLP-1 is within minutes 
truncated by the serine protease dipeptidyl-peptidase-4 (DPP-4 a.k.a. CD26) at the 
alanine in the second amino acid position at the N-terminal to the metabolites GLP-
1(9-37) and GLP-1(9-36)amide, which have 1,000 fold lower affinity for the GLP-1 
receptor (GLP-1R) and lack insulinotropic activity [111, 112].  
 
GLP-1 exerts its actions through the GLP-1R, a G protein-coupled receptor, first cloned 
from rat pancreatic islets [113]. GLP-1R expression has since then been reported in the 
pancreas, kidney, lung, central and peripheral nervous system, gastrointestinal tract, 
and the cardiovascular system. Then again, recently critique has arisen against the 
commercially available antibodies used to detect GLP-1R [114, 115].  Panjwani et al 
[114] detected immunoreactivity against proteins with a size consistent with the GLP-
1R in lung tissue from GLP-1R-/- mice and when using PCR to detect expression of full 
length glp-1r mRNA transcript, no detection was seen in murine macrophages or 
hepatocytes, contrary to previous reports [116, 117]. These findings have raised 
concerns for studies reporting GLP-1R expression in cells and tissues without careful 
controls to thoroughly evaluate the presence or absence of full length glp-1r mRNA 
transcript and protein. This has engendered an interest in developing both new 
antibodies, that are more rigorously verified to be detecting the known GLP-1R [118], 
and other antibody-independent approaches to detect GLP-1R positive cells [115].   
 
GLP-1 exerts pleiotropic effects in the body, both direct and indirect. It increases 
insulin and decreases glucagon secretion from the pancreas in a glucose dependent 
manner, thus controlling prandial glycemia. Beside these insulinotropic and 
glucagonostatic effects, GLP-1 has also been shown to increase, β-cell proliferation 
[119], insulin synthesis [106, 120] and to protect β-cells from apoptosis [121] in animal 
models and in human islets ex vivo. GLP-1 has also been reported to decrease 
appetite, gastric emptying and motility in the intestine. It also indirectly increases 
peripheral insulin sensitivity and decreases the glucose production from the liver. In 
addition and more related to the scope of this thesis, GLP-1 has been demonstrated to 
exert direct effects on the cardiovascular system [109, 122], which will be more 
thoroughly discussed below. 
 
1.4.1 GLP-1 receptor agonists and DPP-4 inhibitors  
GLP-1(7-36)amide has a half-life of approximately 2 minutes before it is degraded by 
DPP-4, which is ubiquitously expressed by many cell types, and also found as a soluble 
form in the circulation, thus complicating the application of GLP-1 for clinical 
treatment of diabetes [103]. Therefore have strategies to increase the presence of 
GLP-1 in the blood, either by using degradation resistant GLP-1R agonists (figure 4) or 
by inhibiting DPP-4 activity, been developed for the treatment of T2DM. 
 
Exendin-4 is a naturally occurring peptide in the salivary gland venom of the Gila 
monster (Heloderma Suspectum). It was given its name since it was the fourth peptide 
to be found in an exocrine organ but shown to exert endocrine actions. Exendin-4 
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consists of 39 amino acids, which share 53 % homology with human GLP-1 [123, 124]. 
However unlike GLP-1, exendin-4 has a much longer half-life (~60-90 minutes). This 
since the alanine in the second amino acid position in the N-terminal region of GLP-1, 
which is site for DPP-4 cleavage, is replaced by glycine making exendin-4 resistant to 
degradation by DPP-4 [111]. Exendin-4 activates the GLP-1R and actually binds to it 
with greater affinity than native GLP-1 [125]. There is also a truncated form of 
exendin, exendin (9-39), which also binds to the receptor, but is unable to activate it, 
thus in effect serving as a GLP-1R antagonist [125]. Exenatide (Byetta®) is a synthetic 
form of exendin-4, which is approved for treatment of T2DM both in the U.S. and in 
Europe [126]. Exenatide is given twice daily as a subcutaneous injection and lowers 
both fasting and postprandial blood glucose; it has also been associated with a weight 
loss of 3-6 kg over 52 weeks. Since 2011, there is also an extended release formulation 
of exenatide available, exenatide LAR (Bydureon®), with a half-life of 4 days in the 
circulation. It represents the first once-weekly injectable anti-diabetic agent [126].  
 
Liraglutide (Victoza®) is another GLP-1R agonist approved for treatment of T2DM. It 
shares 97% homology to the native peptide with an arginine 34 lysine substitution and 
a glutamic acid bound to a FFA addition to lysine 26. However, and unlike exendin-4, 
liraglutide is only partly resistant to DPP-4 degradation; but due to the FFA addition it 
can bind to albumin, shielding the DPP-4 cleavage site, thus extending its half-life to 
10-14 hours [111]. Liraglutide, taken as a subcutaneous injection once daily, reduces 
both fasting and postprandial glucose levels and is associated with a weight loss of up 
to 2.5 kg after 30 weeks of treatment [111, 126].  
 
Lixisenatide (Lyxumia®), a derivative of exenatide and administered subcutaneously 
once daily, was approved for treatment of T2DM in Europe in 2013. As expected, 
lixisenatide has effects on postprandial and fasting blood glucose levels in patients 
both as monotherapy and in combination with other anti-diabetic agents [127]. The 
pronounced effects of lixisenatide on postprandial blood glucose levels [128] have 
provided a clear rationale for combining it with basal insulin. This combination has 
been evaluated in three studies and been shown to be well tolerated. It signiﬁcantly 
improved glycemic control, with a limited risk of hypoglycemia and a beneﬁcial effect 
on body weight, either weight loss or no weight gain, which is important since insulin 
treatment otherwise is coupled to a body weight gain [127]. 
 
There are also other GLP-1R agonists under late-stage development, such as 
semaglutide, albiglutide and dulaglutide; however, none of them has as of yet been 
approved for treatment of T2DM [126].  
 
Another way to address the issue with the rapid degradation of GLP-1 is to directly 
target DPP-4. Sitagliptin (Januvia®) was in 2006 the first DPP-4 inhibitor to be 
approved in the U.S. for treatment of T2DM [129]; since then several others, i.e. 
alogliptin (Nesina®), linagliptin (Trajenta®), saxagliptin (Onglyza®) and vildagliptin 
(Galvus®) have become commercially available. An advantage that DPP-4 inhibitors 
have compared to GLP-1R agonists is that they can be taken orally instead of as a 
subcutaneous injection. In contrast to GLP-1R agonists, DPP-4 inhibitors are almost 
weight neutral, which might be due to the modest increase in GLP-1 levels (15-25 
pmol/L), compared to the pharmacological levels in plasma of the GLP-1R agonists 
[111]. Since numerous peptides have an alanine or a proline at position two, making 
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them susceptible to DPP-4 cleavage, it is hard to precisely pin point the peptide that 
mediate the glucose lowering effect of DPP-4 inhibitors. Notwithstanding this, in mice 
lacking both the GLP-1R and the GIP receptor, DPP-4 inhibitors lose their ability to 
lower blood glucose [130].  
 
 
 
 
 
 
Figure 4. Structure of native GLP-1 and GLP-1 analogues. Reproduced with permission from Bolli GB., et 
al., Diabetes Obes Metab. 2013 Dec 24. Copyright ©2013 John Wiley & Sons Ltd. 
 
1.4.2 Effects of treatment on vascular function  
 
Over the years it has become evident that GLP-1, besides its insulinotropic actions, 
also exerts extrapancreatic effects, so also in the cardiovascular system [131-133]. The 
GLP-1R has been shown to be expressed both in the vasculature and the heart [118, 
134, 135]. Since there is an uncertainty regarding the specificity of the GLP-1R 
antibodies, discussed above, the GLP-1R expression in the vasculature might need 
some additional verification. However, numerous studies have repeatedly shown 
effects of GLP-1 on blood pressure, heart rate, ischemia/reperfusion injury, 
coagulability, inflammation and on vascular endothelial function [136]. Adding to this, 
the GLP-1 metabolite GLP-1(9-36)amide, which has very low affinity for the GLP-1R, 
has been shown to induce vasodilation in rat and mouse arteries ex vivo [135, 137] 
and to increase the functional recovery from ischemia/reperfusion injury in the heart 
of both wild-type and GLP-1R-/- mice [135]. Remarkably, in the same study, exendin-4 
was shown to have a partial cardioprotective effect in a GLP-1R-independent manner 
[135]. 
 
Richter et al were the first to demonstrate the GLP-1 exerted vasodilatory properties 
on rat artery rings. Upon removal of the endothelium, the relaxing effect of GLP-1 was 
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abolished, leading the authors to conclude that the effect was endothelium-
dependent [138]. The vasodilatory response of GLP-1 was blocked in mesenteric 
arteries using L-NNA, a NOS inhibitor, further supporting the involvement of NO and 
the endothelium [135]. Since then this has also been observed in humans, in as much 
as a continuous infusion of GLP-1 improved endothelial dysfunction in T2DM patients 
with coronary artery disease compared to saline, measured by flow mediated dilation 
(FMD) [134]. Further supporting this, several other studies have shown similar effects 
of exendin-4 and DPP-4 inhibitors [139-144]. Even a single subcutaneous injection of 
exendin-4 improved postprandial endothelial dysfunction in newly diagnosed T2DM 
after a high fat meal [145]. However, there are also studies reporting no effect of GLP-
1R agonists on endothelial function [146, 147] and even one study where the FMD 
was worsened after treatment with the DPP-4 inhibitors sitagliptin and alogliptin 
[148]. What distinguishes most of these studies from each other is the duration of the 
treatment. The majority of the studies showing positive effects on endothelial 
functions were either acute or no longer than four weeks. Studies showing no effect 
or even a worsened effect had a longer duration, making compliance to the 
medication a factor to consider.  
 
Beneficial effects of GLP-1 and GLP-1R agonists on markers of endothelial cell 
dysfunction and cardiovascular risk have also been noted in vitro. GLP-1 and exendin-4 
increase NO production and stimulate proliferation of human endothelial cells, 
through phosphatidylinositol-3 kinase (PI3K)/Akt-, protein kinase A (PKA)- and eNOS 
dependent pathways [149]. Liraglutide has been shown to reduce both the 
inflammatory cytokine tumor necrosis factor-α - (TNF-α) and hyperglycemia-induced 
expression of the fibrinolysis inhibitor PAI-1 and vascular adhesion molecules VCAM-1 
and ICAM-1 [150]. Liraglutide also reduced TNF-α- and hyperglycemia-induced 
oxidative stress by inhibiting PKC translocation to the cellular membrane and thus 
reducing subsequent activation and superoxide production by NADPH oxidase [151, 
152]. Liraglutide could also protect from TNF-α-induced apoptosis [151] ER stress and 
ER stress associated DNA damage [153]. Additionally, GLP-1 has been shown to 
protect from AGE-induced cell death [154]. 
 
GLP-1, GIP and exendin-4 have been shown to reduce monocyte adhesion, 
macrophage infiltration and atherosclerotic lesions in the vascular wall of apoE-/-  
mice, a commonly used animal model for studying the development of atherosclerosis 
[116, 155]. This effect was suggested by the authors to involve reduced foam cell 
formation, because oxLDL-induced cholesteryl ester accumulation was significantly 
decreased in macrophages harvested from GLP-1- and GIP-treated animals [155]. In 
contrast, others have reported that the GLP-1R agonist taspoglutide had no effect on 
the aortic plaque area in apoE-/- mice on a high fat diet, with a streptozotocin-induced 
hyperglycemia to simulate T2DM [114]. Thus the effect of GLP-1 on atherosclerosis 
development is still unclear, and more data on atherosclerosis associated outcomes, 
especially in diabetic humans, after long term treatment with incretin-based therapy is 
much needed.  
 
GLP-1 has been suggested to exert direct effects on SMCs. In line with this our group 
noted that a vasodilatory effect of GLP-1 on femoral arteries ex vivo was evident even 
with inhibition of NOS and stripping of the endothelium [156]. Also, exendin-4 
treatment has been shown to decrease intimal hyperplasia in a mouse model of 
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vascular injury, as well as in insulin-resistant rats in vivo, and to reduce SMC 
proliferation in vitro [157-159]. However the molecular mechanisms mediating this 
effect have not yet been elucidated.  
 
Recently, two large clinical studies investigating the cardiovascular safety of the DPP-4 
inhibitors alogliptin (EXAMINE) [160] and saxagliptin (SAVOR-TIMI 53) [161] were 
published. There was no reduced risk of fatal or non-fatal cardiac events, and in the 
SAVOR-TIMI 53 the rate of hospitalization for heart failure was even slightly increased 
for patients treated with saxagliptin. However, the patients were followed for a 
median of 18 months in the EXAMINE trial and a median of 25 months in the SAVOR-
TIMI 53 study. As has been evident form other studies, such as the UKPDS, the effect 
on macrovascular complications might not be seen until after at least 10 years [31]. 
Other large studies, evaluating the cardiovascular outcome of GLP-1R agonists and 
DPP-4 inhibitors, are underway [162].  
 
1.5 METFORMIN 
 
Metformin (dimethylbiguanide) is an oral anti-diabetic agent of the biguanide family, 
and is currently used as first-line treatment of T2DM [163]. Metformin has a botanical 
origin in the Galega officinalis, which was used as an herbal remedy in medieval 
Europe to treat various conditions such as polyuria and plague. The first publication 
suggesting its anti-diabetic properties was published already in the 17th century [164-
166]. Galega officinalis is rich in guanidine which has hypoglycemic properties in 
animals, but it was too toxic for clinical use. In 1922, the interest for guanidine 
derivatives led to the synthesis of several biguanides, including dimethylbiguanide 
[167], but it would take until the end of the 1950s before metformin (Glucophage®) 
was scientifically and clinically characterized, by Jean Sterne [165].  
 
Treatment with metformin is associated with less hypoglycemic events and less or no 
weight gain when compared to insulin and sulfonylurea treatment. It is not completely 
known how metformin lowers blood glucose, but it decreases insulin resistance and 
reduces fasting insulin levels. Evidence from clinical and animal studies is however 
growing, suggesting that the primary function of metformin is to decrease hepatic 
glucose production, via decreased gluconeogenesis [163]. Metformin is believed to 
exert its pharmacological effects through AMP-activated protein kinase (AMPK) [168]. 
Interestingly, metformin induces secretion of GLP-1 from GLP-1-producing cells in 
vitro [169], increases total plasma GLP-1 levels in vivo [170] and 4 weeks of metformin 
treatment increased fasting plasma GLP-1 levels in diabetic subjects. Metformin 
treatment also augmented total plasma GLP-1 levels in both diabetic and non-diabetic 
subjects after an oral glucose load [171]. Moreover, metformin has been shown to 
protect human pancreatic islets ex vivo from functional abnormalities induced by 
glucotoxicity [172], lipotoxicity-induced impairment of  glucose responsiveness and 
glucose metabolism [173], and apoptosis by reducing oxidative stress [174]. 
 
1.5.1 Effects of treatment on vascular function 
 
In a substudy of the UKPDS, monotherapy with metformin decreased the incidence of 
macrovascular morbidity in overweight T2DM patients, compared to the control 
group, an effect that was not seen in the intensive treatment arm with insulin and 
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sulfonylurea. This outcome appeared to be independent of it glucose lowering 
property and it was suggested that it might be coupled to the decrease in PAI-1 levels 
seen with metformin treatment [175]. 
 
As mentioned above, metformin is believed to exert its pharmacological effects 
through AMPK activation [168]. AMPK has emerged as a new potential target in 
reversing endothelial dysfunction, both direct [176] and metformin-induced [177]  
activation of AMPK, has been demonstrated to lead to phosphorylation of eNOS, thus 
stimulating the release of NO, which is important for vascular function [168, 178]. In 
line with this, metformin improved endothelial function in vivo, by reducing ER stress, 
superoxide production  and increasing NO bioavailability in mice on a high fat diet, an 
effect that involved the AMPK/peroxisome proliferator-activated receptor δ (PPAR δ) 
pathway [179]. Metformin was also shown to modulate oxidative stress caused by 
hyperglycemia. By decreasing DAG levels, PKC translocation to the cellular membrane 
was inhibited, and subsequent activation and superoxide production by the NADPH 
oxidase was thus reduced, an effect that was suggested to involve AMPK [152]. 
Activation of AMPK by 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) 
has also been shown to protect from palmitate-induced apoptosis through 
suppression of ROS production in bovine aortic endothelial cells [72].  
 
1.6 EFFECTS OF OTHER ANTI-DIABETIC AND CARDIOPROTECTIVE AGENTS ON 
ENDOTHELIAL CELL FUNCTION 
 
1.6.1 Insulin 
 
Insulin is the main regulator of glycemia in the body. It increases uptake of glucose 
into skeletal muscle and adipose tissue by regulation of GLUT-4 translocation to the 
cell surface. Besides glucose, insulin also promotes the uptake of FFAs and amino acids 
into cells. Insulin is an anabolic hormone, and it promotes synthesis and storage of 
carbohydrates, lipids, and proteins, while inhibiting their degradation and release into 
the circulation [180]. Insulin appears to have vasoactive effects in a NO-dependent 
manner [181, 182]. However, whether this occurs under physiological conditions is 
still a matter of debate [183, 184]. The insulin receptor is expressed on human 
coronary artery endothelial cells (HCAEC) [185] and activation of the receptor on 
endothelial cells leads downstream to PI3K/Akt dependent phosphorylation of eNOS 
at serine1177 and stimulation of NO production [186]. Insulin has also been reported to 
protect human umbilical vein endothelial cells (HUVECs) from palmitate-induced 
apoptosis through activation of the PI3K/Akt pathway [187]. 
 
Exposure of endothelial cells to FFAs impairs insulin-dependent phosphorylation of 
IRS-1, Akt and eNOS, through increased IRS-1 serine instead of tyrosine 
phosphorylation. Increased serine phosphorylation leads to a decreased PI3K 
activation, impairing the endothelial insulin sensitivity [69]. FFAs are not the only 
stimuli that may impair PI3K activation at the level of IRS 1 and 2; this phenomenon 
has been detected with TNF-α and angiotensin-II exposure and upon PKC activation. 
However, this resistance to insulin is somewhat “selective” because the other major 
pathway of insulin signaling, the mitogen-activated protein kinase (MAPK) pathway, is 
left unaffected. The MAPK, extracellular-signal-regulated kinase 1/2 (ERK 1/2) is 
responsible for production of the potent vasoconstrictor ET-1, causing an imbalance 
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between vasodilation and vasoconstriction, contributing to endothelial dysfunction 
[42, 188-190]. Insulin resistant individuals have elevated plasma ET-1 levels, and 
continuous infusion of triglycerides (Intralipid®) together with insulin increases ET-1 
secretion in healthy subjects [191].  
 
1.6.2 Sulfonylureas 
 
Sulfonylureas render the β-cell more sensitive to glucose by binding to the 
sulfonylurea receptor (SUR)/Kir 6.2 subunit of the ATP-dependent potassium channel 
(KATP), which depolarizes the β-cell which causes insulin secretion. The KATP channels 
are not β-cell exclusive and can be found on other endocrine cells of the pancreas, in 
the heart, the brain, and in the vasculature on SMCs and the endothelium, thus 
spurring a concern whether binding of sulfonylurea to KATP channels in the heart and 
vasculature is harmful [192]. 
 
In the UKPDS, no increased morbidity and mortality was seen in patients treated with 
sulfonylureas compared to insulin treatment [23]. However, reports on vascular 
effects of sulfonylureas are contradictory. There are studies showing that the 
sulfonylurea glibenclamide exerts a pro-arrhythmic effect at reperfusion after a 
reversible ischemic event in conscious sheep [193] and has negative effects on 
vascular function in humans [194]. Sulfonylureas have also been coupled to an 
increased risk of congestive heart failure in a retrospective cohort study, when 
compared to metformin treatment [195]. Conversely, there are others that have 
shown an improved endothelial function in diabetic rabbits by gliclazide [196] and that 
gliclazide in comparison to glibenclamide attenuates the progression of 
atherosclerosis in humans, measured indirectly by the progression of intima-media 
thickness in the carotid artery [197]. Gliclazide has also been shown to protect from 
glucose-induced apoptosis of endothelial cells by reducing oxidative stress [198]. Also, 
glimepiride -- another sulfonylurea -- but not glibenclamide was shown in vitro to 
stimulate NO production in endothelial cells through PI3K/Akt dependent pathways 
[199, 200] and to reduce TNF-α-induced NF-B activation [200]. 
 
1.6.3 Thiazolidinediones 
 
Thiazolidinediones (TZDs) bind to and activate the PPAR subtype γ. PPARγ is 
ubiquitously expressed in the body and modulates the transcription of insulin-
sensitive genes involved in the regulation of glucose and lipid metabolism in adipose 
tissue, skeletal muscle and liver. Treatment with TZDs improves insulin sensitivity and 
decreases circulating FFAs [201]. There are currently two TZDs on the market, 
rosiglitazone (Avandia®) and pioglitazone (Actos®). 
 
PPARγ agonists modulate various inflammatory processes in the body, and TZDs have 
numerous anti-inflammatory effects [202]. Orasanu et al showed that pioglitazone 
decreased VCAM-1 expression on endothelial cells through modulation of NF-B 
activity in vitro and in vivo, through a PPARα-dependent mechanism [203]. Exposure 
of endothelial cells to rosiglitazone has been shown to stimulate NO synthesis through 
an AMPK-dependent mechanism [204]. Concurrent with this, pioglitazone was shown 
to improve endothelial function in non-diabetic subjects with coronary artery disease, 
suggesting that pioglitazone exerts a direct effect on the endothelium [205].  
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Pioglitazone has been shown in a randomized controlled trial to not significantly 
decrease the large, combined primary cardiovascular end point, although -- and 
importantly -- the secondary clinical end point of stroke, myocardial infarction, and 
cardiovascular death was significantly improved, despite that these patients were on 
extensive cardioprotective background medication. However, an increased incidence 
of edema and heart failure was seen in the pioglitazone- treated group [206]. Edema 
is a well-known side effect of TZD treatment and is more often seen in patients with 
heart failure or with concomitant insulin treatment; however, the mechanism behind 
the development of TZD induced edema is not fully understood [207]. Further 
subgroup analyses, investigating the risk for recurrent MI and stroke, have shown 
protective effects of pioglitazone [208, 209]. 
 
In 2007, a meta-analysis including results from 42 widely different trials involving 
another TZD, rosiglitazone, Nissen et al. reported that treatment with rosiglitazone 
increased the risk for MI and death from cardiovascular causes [210]. As a 
consequence of this, rosiglitazone was revoked from the European market in 2010 
and the U.S Food and Drug Administration (FDA) put it under selling restrictions; 
however, at the end of 2013, the FDA lifted these sanctions [211]. The meta-analysis 
by Nissen et al. has been criticized for overestimating the risk and being limited in its 
inclusion of data [212]. The Rosiglitazone Evaluated for Cardiovascular Outcomes and 
Regulation of Glycemia in Diabetes (RECORD) trial published 2009, which included 
4,447 patients, could not confirm the results reported by Nissen et al. regarding the 
increased risk of cardiovascular morbidity [213].  
 
1.6.4 Statins 
 
Although cholesterol is important and necessary for human health, high levels of 
cholesterol in the blood, and especially LDL cholesterol, are associated with injury to 
arteries and cardiovascular disease. Statins inhibit the rate-limiting enzyme in the 
cholesterol biosynthesis, HMG-CoA reductase, leading to displacement of the natural 
substrate HMG-CoA, which effectively reduces serum cholesterol levels. Beside their 
primary function, statins might also exert direct (pleiotropic) effects on the 
endothelium [214]. Statins have been shown to be involved in the turnover of vascular 
cells; however, the data is somewhat discrepant. Some studies have shown that 
statins render endothelial and SMCs more susceptible to apoptosis, while others have 
shown the opposite or no effect [214]. Statins have also been implicated to attenuate 
plaque inflammation by reducing inflammation within the intima [215] and to 
influence atherosclerotic plaque stability by suppressing the expression of the pro-
coagulant protein, tissue factor, and the extracellular matrix-degrading enzymes, 
matrix metalloproteinases (MMPs) in vivo and in vitro [216, 217] and to reduce 
macrophage content in experimental plaques in vivo [218, 219]. Treatment with 
statins in patients with preexisting cardiovascular disease and in diabetics without 
prior vascular disease has proven to be effective in decreasing mortality [220], but 
their value in primary prevention remains controversial [221, 222].  
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1.6.5 Angiotensin II receptor blockers 
 
Hypertension is a well-established risk factor for cardiovascular disease. Angiotensin II 
receptor blockers (ARBs) are used to treat hypertension. ARBs bind to the angiotensin 
II receptor type 1 (AT1), and by preventing the natural ligand, the vasoconstrictor 
angiotensin II, to bind they induce vasodilation. ARBs also exert effects on the 
vasculature, which are independent of its blood pressure-lowering properties or AT1 
receptor antagonism [223]. ARBs have been suggested to have anti-atherosclerotic 
effects, and have been shown to protect from development and progression of the 
lesions, and to promote plaque stability in experimental atherosclerosis in vivo [224-
226]. In vitro, ARBs have been reported to protect endothelial cells against starvation 
and oxysterol (oxysterols constitute the major toxic component in oxLDL) induced 
apoptosis possibly by downregulating the gene expression of key components in the 
apoptotic machinery [223]. ARBs were also found to protect against hypoxia induced 
cell death, an effect that involved eNOS [227]. Treatment with ARBs increases NO 
release in vitro and ARBs have been shown to improve endothelial function in patients 
with the metabolic syndrome [228]. Candesartan, an ARB, was shown in the CHARM 
trial program to reduce cardiovascular morbidity and mortality in patients with 
chronic heart failure [229].  
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2 AIMS 
 
The overall aim of this thesis was to investigate the role and mechanisms of drugs 
used for the management of type 2 diabetes on proliferation and apoptosis of cells 
in the vasculature under normal and simulated diabetic conditions both in vitro and 
in vivo. 
 
Specific aims: 
- To investigate the roles of anti-diabetic drugs on proliferation and lipotoxicity- 
induced apoptosis in HCAECs.  
- To study the molecular mechanisms underlying the effects of a GLP-1R agonist 
and metformin on lipotoxicity-induced apoptosis of HCAECs. 
- To investigate whether the proliferative and anti-apoptotic effects of a GLP-1R 
agonist noted in vitro on HCAECs are also operative in vivo to improve vascular 
repair and accelerate endothelialization in an animal model of vascular injury. 
- To investigate the mechanisms by which a GLP-1R agonist influence 
proliferation and apoptosis of vascular smooth muscle cells in vitro. 
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3 MATERIALS AND METHODS 
 
3.1 CELL CULTURE 
 
Endothelial cell culture  
Study I-III 
Normal primary HCAECs, isolated from normal human coronary arteries (passage 5-
13) and obtained from Clonetics (Lonza, Walkersville, MD), were grown in EGM-2 MV 
medium supplemented with 5 mM glucose, hydrocortisone, human epidermal growth 
factor , 5 % FBS, vascular endothelial growth factor, human fibroblast growth factor-B, 
R3-IGF-1, ascorbic acid and gentamicin/amphotericin-B at 37°C in a humidified 
atmosphere (5% CO2, 95% air) as recommended by the supplier. Confluent cultures 
were detached by trypsin 0.025 %/EDTA 0.01 % and seeded onto tissue culture dishes 
and allowed to attach overnight before further investigations were performed. 
 
Smooth muscle cell culture 
Study IV  
SMCs were isolated by enzymatic digestion from the aorta of adult Sprague–Dawley 
rats as previously described [230]. Cells were then cultured in F12/Ham medium 
supplemented with 10 % FBS (Gibco, Life Technologies, Carlsbad, CA), 50 µg/ml 
ascorbic acid, 100 units/ml penicillin and 100 µg/ml streptomycin. Confluent cell 
cultures were detached using 0.1 % trypsin and 0.8 g/l EDTA (SVA, Uppsala, Sweden) 
seeded onto tissue culture dishes and allowed to attach overnight before further 
investigations were performed. Cells between passages 4-7 were used for 
experiments.  
 
3.2 VIABILITY 
 
Study I 
Cells were incubated in serum-deficient EGM medium containing 0.5 % FBS and 
2 mM L-glutamine, in the presence or absence of the drugs for 48 h. Cell number was 
manually counted in a hemocytometer and cell viability assessed by Trypan blue 
exclusion. 
 
3.3 [3H]-THYMIDINE INCORPORATION 
 
Study I and IV 
For specific treatment conditions, please refer to each individual article. 
Rates of [3H]-thymidine incorporation into DNA were analyzed and used as a measure 
of DNA synthesis. Cells were pulsed with [3H]-thymidine (1 µCi/ml) 8 h prior to the end 
of the incubation. Cells were then trypsinized, collected and homogenized through 
ultrasonication. Nucleic acids were precipitated in ice-cold 10 % trichloroacetic acid 
for 30 minutes on ice. The precipitate was washed with 10 % trichloroacetic acid and 
[3H]-thymidine incorporation into DNA was measured using a microplate scintillation 
and luminescence counter (Wallac MicroBeta® Trilux, PerkinElmer) [231]. The protein 
concentration of the samples was measured using DC™ Protein Assay according to the 
manufacturer’s instructions (Bio-Rad Laboratories, Hercules, CA). 
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3.4 DNA FRAGMENTATION 
 
Study I-IV 
For specific treatment conditions, please refer to each individual article. 
Cell apoptosis was analyzed using the Cell Death Detection Kit plus (Roche 
Diagnostics) according the manufacturer’s instructions. The Cell Death Detection Kit is 
an ELISA that measures cytoplasmic DNA-histone nucleosome complexes generated 
during apoptotic DNA fragmentation. Samples were measured at 405 nm and 
corrected for background signals caused by irregular microtiter plates or light 
scattering due to solid particles in the solution at the reference wavelength of 492 nm.  
 
3.5 CASPASE-3 ACTIVITY 
 
Study I and II 
Cells were cultured to 90% confluence. After incubation in serum-deficient medium 
overnight, cells were pretreated for 1 h with the drugs or inhibitors, after which the 
incubation was continued for 24 h in the presence of 0.125 mM palmitate/0.25 % BSA 
or vehicle. Caspase-3 activity, a measure of apoptosis, was evaluated using the 
EnzChek® Caspase-3 Assay Kit (Molecular Probes®, Life Technologies) according the 
manufacturer’s instructions. The assay is based on the 7-amino-4-methylcoumarin-
derived substrate Z-DEVD-AMC, which yields a fluorescent product 
(excitation/emission ~342/441 nm) upon proteolytic cleavage by active caspase-3. All 
results were normalized to the protein concentration of the corresponding sample 
using DC™ Protein Assay (Bio-Rad Laboratories, Hercules, CA). 
 
3.6 MEASUREMENT OF NITRIC OXIDE PRODUCTION 
 
Study II 
Direct measurements of NO release from HCAECs were performed using the cell-
impermeable fluorescence indicator DAF-2 as described [232]. Cells were incubated in 
the presence or absence of palmitate with or without exendin-4 or vehicle in serum-
deficient medium for 24 h. The cells were subsequently washed twice in Krebs-Ringer 
bicarbonate Hepes buffer containing 135 mM NaCl, 3.6 mM KCl, 5 mM NaHCO3, 0.5 
mM NaH2PO4, 0.5 mM MgCl2, 1.5 mM CaCl2, and 10 mM HEPES, pH 7.4, followed by 
an incubation with 5 mM DAF-2 in 0.5 ml Krebs-Ringer bicarbonate Hepes buffer for 2 
h, at 37 oC, using the eNOS substrate L-arginine (100 µM) as positive control. At the 
end of the incubation, supernatants were transferred into black microplates and the 
fluorescence was measured with the fluorescence microplate reader Infinite M200 
(Tecan Group Ltd., Männedorf, Germany) at excitation wavelength of 488 nm and 
emission 515 nm. Results were normalized to the protein concentrations determined 
using BCA kits after the cells in each well were lysed in a lysis buffer containing 80 mM 
Na2HPO4, 20 mM NaH2PO4, 100 mM NaCl, and 1% Triton X-100, pH 7.5. 
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3.7 MEASUREMENT OF INTRACELLULAR REACTIVE OXYGEN SPECIES 
 
Study II and III 
For specific treatment conditions, please refer to each individual article.  
Intracellular ROS levels were measured using Image-iT LIVE Green Reactive Oxygen 
Species Detection Kit (Molecular Probes, Life Technologies Europe BV) as previously 
described [233]. Briefly, the assay is based on 5-(and-6)-carboxy-2’,7’-
dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA), a fluorogenic marker that 
will be cleaved upon the presence of ROS. HCAECs were seeded into 6-well plates. 
Cells were then incubated for 24 h in the presence or absence of palmitate, vehicle, 
drugs or inhibitors. Cells were then washed with Hank’s balanced salt solution before 
adding 25 μM carboxy-H2DCFDA to each well. After 30 minutes of incubation at 37 oC, 
excess probe was removed by washing the cells again with Hank’s balanced salt 
solution. HCAECs were then lysed in PBS containing 1 % Triton X-100. Carboxy-DCF 
fluorescence in cell lysates was detected at an excitation/emission wavelength of 
495/529 nm using a microplate reader (Tecan Group Ltd., Männerdorf, Switzerland). 
The fluorescence intensity was normalized against the protein concentration of each 
individual well. 
 
3.8 GENE SILENCING  
 
Study II 
HCAECs were seeded into 100-mm dishes at a density of 2.5 × 105 cells per dish and 
incubated for 24 h at 37°C in complete medium. The cells were washed twice with 
culture medium without serum and supplement. Control siRNA/eNOS siRNA (10 nM) 
was mixed and incubated with SilenceMag according to the standard protocol (Oz 
Biosciences, Marseille, France). After incubation with a magnetic field for 15 min, the 
magnet was removed from the culture plate. 8-24 h post transfection, the media in 
the cell culture plate were replaced with complete medium containing 5 % FBS and 
then further incubated for 24 h. The cells were harvested and centrifuged at 200 g for 
2 min to remove the supernatant.  
  
3.9 ISOLATION OF TOTAL RNA AND REAL-TIME PCR  
 
Study II 
Total RNA was extracted from cells treated with eNOS siRNA and control siRNA, using 
Aurum Total RNA Mini kit, and reversely transcribed into complementary DNA with 
iScriptTM cDNA Synthesis kit according to the manufacturer’s instructions (Bio-Rad 
Laboratories, Hercules, CA). The PCR reaction mixture contained, in a final volume of 
20 µl, 4 µl of cDNA, 10 µl of KAPA SYBR FAST qPCR master mix (Kapa Biosystems, 
Wilmington, MA) and corresponding primers [234]. The gene expression level was 
normalized to the housekeeping gene, β-actin. 
 
Table 1. Primer sequences 
Primer targets, human Forward primer Reverse primer 
NOS3 5’-GTGATGGCGAAGCGAGTGAAF-3’ 5’- CCGAGCCCGAACACACAGAAC-3’ 
ACTB 5’-AGCGGGAAATCGTGCGTG-3’ 5’-CAGGGTACATGGTGGTGCC-3’ 
  
 
 26 
3.10 WESTERN BLOT 
 
Study II-IV 
Protein samples from cells were prepared for Western blot analysis using a modified 
RIPA buffer, containing 20 mM Trizma base, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 
0.25 % Na-deoxycholate, 2 mM EDTA, 1 mM Na3VO4, 50 mM NaF and 1% protease 
inhibitory cocktail (Sigma P-8340). After lysis the cell extracts were centrifuged at 4 oC 
and supernatants were transferred to another set of tubes. Protein concentration was 
determined by the DC™ protein assay according to the manufacturer’s instructions 
(Bio-Rad Laboratories, Hercules, CA) and cell extracts were stored at -80 oC pending 
further analysis. Equal amounts of protein (15-30µg) were then mixed with reducing 
SDS-PAGE sample buffer, boiled for 5 min and proteins separated by electrophoreses 
against a pre-stained protein ladder on a 10-15 % polyacrylamide gel under 
denaturing conditions, followed by transfer to a polyvinylidene diflouride membrane. 
Immunoblot analyses were performed using antibodies that recognize phosphorylated 
ERK 1/2 (Millipore Corporatin, Billierica, MA), total ERK 1/2, phosphorylated Akt, total 
Akt (Santa Cruz Biotechnology, Heidelberg, Germany), phosphorylated AMPK, total 
AMPK, phosphorylated p38 MAPK, total p38 MAPK, phosphorylated c-Jun N-terminal 
kinase (JNK), total JNK, phosphorylated eNOS and total eNOS, cleaved caspase-3 (Cell 
Signaling Technology, Danvers, MA). Immunoreactive bands were detected using 
enhanced chemiluminescence (GE Healthcare, Uppsala, Sweden), imaged with 
Molecular Imager ChemiDoc XRS and quantified with Quantity One software v. 4.6.5 
(Bio-Rad Laboratories, Hercules, CA). Phosphorylation levels were determined after 
normalization with total forms of the protein. α-tubulin or staining of the membranes 
with Coomassie Brilliant Blue (Bio-Rad Laboratories) were then used to verify equal 
protein loading. 
 
3.11 IN VIVO STUDY DESIGN 
Study IV 
The study was performed according to the guidelines of Karolinska Institutet and 
approved by the local animal ethics committee (N479/12). The number of animals in 
the experiment was chosen after power calculations based on a pilot experiment. 40 
male Sprague-Dawley rats (~400 g) were used for the study. The animals were kept in 
groups through the whole length of the experiment in enriched cages. After arterial 
injury, the animals were randomized by a blinded operator for treatment either with 
exendin-4 (1 nmol/day) or saline. The treatments were given through a four week long 
continuous infusion by an osmotic ALZET® pump (2ML4) (DURECT Corporation, 
Cupertino, CA), placed subcutaneously on the back. Before surgery, after 2 weeks and 
at sacrifice, body weight and prandial blood glucose levels were monitored. At the 
same time blood samples were taken to analyze serum insulin and FFA levels. 
 
3.12 ARTERIAL INJURY MODEL 
 
Study IV 
Carotid artery balloon injury and placement of osmotic ALZET® pump were 
performed under isoflurane inhalation anesthesia (4 % at induction and 1.5-2 % 
during the procedure). The rats were placed on a heating pad during surgery and 
ultrasound examinations and eye protection gel was used. After exposure of the left 
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carotid artery, an arteriotomy was performed in the external carotid artery and a 2F 
Fogarty embolectomy catheter was inserted into the left common carotid artery. 
The catheter was then advanced into the aortic arch, inflated and withdrawn with 
simultaneous rotation through the whole length of the artery while inflated. The 
passage was repeated three times in order to remove the endothelial layer. The 
external carotid artery was then ligated and the skin wound closed [235]. The animal 
was then turned onto its stomach, the osmotic ALZET® pump was placed 
subcutaneously on the back and the skin wound was closed. The animals were given 
Buprenorfin (Temgesic®) at 0.01 mg/kg body weight subcutaneously at the time of 
surgery, 12 and 24 h post procedure. The animals were controlled daily for pain 
signs and given additional analgesia when necessary.  
 
3.13 ULTRASOUND VISUALIZATION AND MEASUREMENTS 
Study IV 
Ultrasound biomicroscopy has been shown to be a useful tool for the assessment of 
intimal hyperplasia and lumen diameter in the rat carotid injury model [235]. In 
study IV, a high-resolution ultrasound system (Vevo 2100, Visualsonics Inc., Toronto, 
Ontario, Canada), equipped with a MS700 transducer (up to 70 MHz), was used for 
in vivo evaluation of intimal hyperplasia and lumen diameter of the carotid arteries 2 
and 4 weeks after the injury. The arteries were visualized longitudinally under 
isoflurane anesthesia (4 % at induction, 1.5-2 % during the examination) and the cine 
loops were saved for off-line measurements. Intima, media and whole vessel wall 
thickness were measured 10 mm proximal to the carotid bifurcation on the far wall 
of the artery in diastole using leading edge principle [235]. Arterial lumen was 
measured at systole and diastole just below and 10 mm proximal to the carotid 
bifurcation. The elasticity in terms of strain of the arterial wall was assessed just 
below the carotid artery bifurcation and calculated as percentage (systolic lumen 
diameter – diastolic lumen diameter) / diastolic lumen diameter * 100. The same 
observer made all the measurements in a blinded manner [236, 237]. 
 
3.14 SACRIFICE AND EVALUATION OF RE-ENDOTHELIALIZATION 
Study IV 
After 4 weeks of treatment, the re-endothelialization process was evaluated using 
Evans blue dye. Anesthetized rats were injected with 1 ml of 2 % Evans Blue, which 
was allowed to circulate for 15 minutes before animals were sacrificed by an 
overdose isoflurane and perfused with NaCl. The left common carotid artery was 
harvested and placed in saline, cut longitudinally and pinned open onto paraffin 
plates. Images of the vessels were taken using a dissection microscope (Leica EZ4D) 
for subsequent analysis of the re-endothelialization process. The total and the re-
endothelialized areas (white areas, not stained with Evans Blue dye) of the artery 
were determined using the manual tracking tool in ImageJ software [238].   
 
3.15 DETERMINATION OF SERUM PARAMETERS 
 
Study IV 
Prandial blood glucose levels were measured on saphenous vein blood at the same 
time in the morning, using a glucometer (OneTouch Ultra2; LifeScan, Milpitas, CA) at 
three time points, viz. study start (week 0), after 2 weeks and at sacrifice by week 4. 
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Serum levels of insulin were determined using a rat ultrasensitive insulin ELISA, 
(Mercodia, Uppsala, Sweden), according to the manufacturer’s instructions. Serum 
concentrations of FFAs were measured using a “NEFA-HR(2) reagent”, an enzymatic 
colorimetric method assay (Wako Chemicals GmbH, Neuss, Germany) according to the 
manufacturer’s recommendation.   
 
3.16 MASSON TRICHROME STAINING 
 
Study IV 
After the common carotid arteries were pinned and photographed for assessment of 
re-endothelialization, the samples were fixed with 4 % formalin for 24 h and then 
placed in 70 % ethanol. The samples were embedded in paraffin and cross-sectioned 
(5 µm). Sections at a distance of 10 mm from the bifurcation were stained with 
Masson Trichrome (Sigma Aldrich, St. Louis, MO) for subsequent morphometric 
analysis of the intima area. Image screening and photography of stained sections were 
performed using ScanScope CS slide scanner (Aperio, CA). Intima and media areas 
were blindly measured on five transverse sections from each animal using NDP-view 
software (Hamamatsu, Japan).   
 
3.17 IMMUNOHISTOCHEMISTRY 
 
Study IV 
The common carotid arteries were fixed with 4 % formalin for 24 h and then placed in 
70 % ethanol. The samples were embedded in paraffin and cross-sectioned (5 µm). In 
order to identify proliferating cells, the slides were stained using an antibody against 
proliferating cell nuclear antigen (PCNA) (DAKO, Glostrup, Denmark; 1:400) [239]. 
Three representative areas, evenly spaced, on each vessel were blindly counted to 
evaluate the percentage of PCNA-positive cells, using Image J software [238]. The total 
number of cells and the total number of PCNA-positive cells were then divided by the 
area to determine the total number of cells and the total number of PCNA-positive 
cells per area unit. Image screening and photography of stained sections were 
performed using ScanScope CS slide scanner (Aperio, CA) and NDP-view software 
(Hamamatsu, Japan). 
 
3.18 STATISTICAL ANALYSIS 
All data are expressed as mean ± SEM. Student’s t test was used to compare the 
difference between two groups. For multiple comparisons, one-way ANOVA or 
Kruskal-Wallis test (where appropriate), followed by the post-hoc tests Student–
Newman–Keuls or Dunn’s were used to determine statistical probabilities of 
differences between groups. Data was analyzed using the SigmaPlot v.11 software. A 
value of p<0.05 was considered statistically significant. 
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4 RESULTS AND DISCUSSION 
 
Patients suffering from T2DM have a two-four times increased risk of a MI and stroke 
[20] and it is estimated that up to 80 % of the mortality in this group is due to a 
thrombotic event [240]. In people with T2DM and insulin resistance, endothelial 
dysfunction is a common finding and endothelial dysfunction is thought to be an early 
and important predictor for developing atherosclerosis and cardiovascular disease 
[42]. With the association between hyperglycemia and macrovascular complications 
not fully understood, together with the increasing global burden of T2DM [4], the 
importance of finding other strategies to improve cardiovascular outcome in T2DM 
patients has emerged as an urgent issue to be addressed. It has therefore been our 
aim to investigate how agents used for T2DM management directly, and not through 
their primary mechanism of action, affect the vasculature under both normal and 
simulated diabetic conditions.  
 
4.1 PROLIFERATION OF HCAECs IS INDUCED UNDER NORMAL AND SIMULATED 
HYPERGLYCEMIC CONDITIONS 
In study I, we set out to scan a number of agents that are currently on the market, and 
used within the treatment regime for T2DM, or in a developmental phase. We tested 
how these compounds affected viability and regeneration of HCAECs in vitro. We 
found that: insulin, metformin, rosuvastatin, pioglitazone, candesartan, glimepiride 
and the novel antidiabetic agent BLX-1002 could all significantly increase the viability 
of HCAECs when they were exposed to serum starvation. Insulin, metformin, 
rosuvastatin and BLX-1002 were also able to increase the proliferation of the cells 
under normal glucose conditions, as measured by [3H]-thymidine incorporation rates. 
However, when the glucose concentration was raised to 11 mM, only insulin and BLX-
1002 were still able to exert a positive effect on HCAEC regeneration. In the 
vasculature, damaged endothelial cells are usually rapidly replaced by proliferating 
healthy resident endothelial cells, thus maintaining endothelial integrity and 
protecting the vessel from development of atherosclerotic lesions [241]. However, 
hyperglycemia has been reported to induce proliferative dysfunction, oxidative stress 
and apoptosis of endothelial cells, thus making the already stressed diabetic 
vasculature even more susceptible to vascular complications [242-245]. Our findings 
that insulin and BLX-1002 stimulate proliferation of endothelial cells even under 
hyperglycemic conditions might therefore contribute to dampening or delaying the 
development of atherosclerosis. It may also contribute to preserving the endothelial 
integrity by inducing a more rapid healing response upon endothelial cell injury or 
apoptosis, hence protecting the vessel wall from thrombotic events [241]. We did not 
investigate the molecular mechanisms involved in the agents’ proliferative effect on 
HCAECs, which is a limitation of study I. Notwithstanding this, insulin and rosuvastatin 
have previously been shown to activate the PI3K/Akt pathway, which is well known to 
be involved in survival and proliferation of cells [186, 246, 247]. Also BLX-1002, which 
is a novel TZD without known affinity for PPARγ, has been shown to signal through 
PI3K in β-cells [248]. Somewhat surprisingly we detected a slight but significant 
increase of [3H]-thymidine incorporation in HCAEC in the presence of metformin [96]. 
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Then again, this might be a reflection of metformin-induced NO formation [177], 
which is important for function, survival and growth of endothelial cells [48, 249].  
 
4.2 HCAECs ARE PROTECTED FROM FFA INDUCED APOPTOSIS 
In study I, II and III we investigated various agents’ effect on apoptosis induced by the 
FFA palmitate. Diabetic patients, independent of their glucose control, have been 
shown to have more endothelial cells circulating in the blood than healthy controls, 
which might be an indication of vascular injury [250]. Elevated levels of FFAs are 
frequently found in patients with T2DM [251] and FFAs have been shown to impair 
endothelial function in vivo [67], in humans [252] and to induce apoptosis of 
endothelial cells in vitro [71], which might impair the integrity of the endothelium. Our 
data from study I showed that insulin, BLX-1002, metformin, pioglitazone and 
candesartan all attenuated the palmitate-induced cleaved caspase-3 activity and 
decreased the apoptotic DNA fragmentation. Again, in this scanning study, no 
molecular mechanisms were explored, but our findings are in line with others. Insulin, 
at supraphysiological concentrations, has been shown to protect from FFA-induced 
apoptosis through activation of the PI3K/Akt pathway [187]. BLX-1002 is a novel 
compound and not much is known about its effect on cellular signaling, but BLX- 1002 
is able to activate PI3K and AMPK in β-cells [248], which have been demonstrated to 
convey anti-apoptotic signals in other cell types [72, 253, 254]. To the best of our 
knowledge, the effects of pioglitazone and candesartan on lipoapoptosis of 
endothelial cells have never been evaluated. However, both pioglitazone and 
candesartan have previously been shown to decrease caspase-3 activity and reduce 
apoptosis in endothelial cells exposed to TNF-α and hypoxia, respectively [227, 255].  
 
In study II and III we continued to focus on apoptosis induced by the FFA palmitate 
but this time we tried to elucidate some of the molecular pathways involved. In study 
II, we investigated the effect of the GLP-1R agonist exendin-4. Previous findings from 
our group showed that exendin-4 activates the GLP-1R in HCAEC, leading to 
phosphorylation of eNOS and subsequent NO production [149]. Upon receptor 
activation, exendin-4 also increases cell proliferation through PKA-, PI3K/Akt- and 
eNOS-dependent pathways. Although GLP-1 has previously been shown to have anti-
apoptotic effects in endothelial cells [151], cardiomyocytes [256] and neuronal cells 
[257], to this end and to the best of our knowledge, no one has studied the effect of 
GLP-1R activation on lipid-induced apoptosis of endothelial cells. Exposure of 
palmitate to HCAECs increased caspase-3 activity and apoptosis, which were dose-
dependently reduced upon co-incubation with exendin-4. Even though exendin-4 is a 
known receptor agonist [125], we wanted to verify the involvement of the receptor, 
since there have been reports of differential effects of exendin-4 and GLP-1 on the 
vasculature, and that the GLP-1 metabolite GLP-1 (9-36) has vasoactive properties 
[135, 137]. These findings suggest that there might be a differential pathway involved 
or the existence of a second GLP-1R. We therefore introduced the receptor antagonist 
exendin (9-39) in our experiments. Co-incubation with exendin-4 and exendin (9-39) 
abolished the anti-apoptotic effect of exendin-4 and in addition GLP-1 (9-36) failed to 
protect the cells from lipoapoptosis, further supporting that the protective effect of 
exendin-4 is mediated via the canonical GLP-1R. Most effects of GLP-1R activation are 
downstream mediated through an increase in cAMP and subsequent PKA activation 
[258]; we therefore both blocked and activated PKA to confirm its involvement. 
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Blocking PKA inhibited the lipoprotective effect, whereas activation of PKA mimicked 
the effect of exendin-4, leading us to conclude that that PKA activity conveys the anti-
apoptotic signals of exendin-4. Downstream of GLP-1R signaling, the PI3K/Akt 
pathway has been implicated in protection against apoptosis [259] and activation of 
PI3K/Akt has previously been shown to protect against lipoapoptosis of endothelial 
cells [187]. We therefore studied the effect of co-incubation with palmitate and 
exendin-4 on phosphorylation of Akt, and inhibiting PI3K and Akt with 
pharmacological inhibitors. Exendin-4 was able to increase Akt phosphorylation in the 
presence of palmitate and -- in further support of the importance of this pathway -- 
inhibition of PI3K and Akt abrogated the protective effect of exendin-4.  
 
In study III, we wanted to elucidate the mechanism behind the lipoprotective effect of 
metformin found in study I. We hypothesized that the protective effect of metformin 
might be due to an AMPK-specific effect, since specific AMPK activation has previously 
been demonstrated to protect bovine aortic endothelial cells from lipoapoptosis [72] 
as well as HUVECs from hyperglycemia-induced apoptosis [260]. Our findings lend 
support to the notion that AMPK signaling can protect from apoptosis, since blocking 
AMPK led to a loss of metformin’s protective effect, while pharmacological activation 
of AMPK mimicked the lipoprotection exerted by metformin. As expected, treatment 
with metformin led to an increased phosphorylation of AMPK, which was sustained 
even in the presence of palmitate. Surprisingly, palmitate, slightly but significantly, 
also increased phosphorylation of AMPK, as has previously been reported in myocytes 
[261]. This might be a reflection of an increased FFA oxidation caused by AMPK 
activation [178], and palmitate in combination with AMPK activity has been shown to 
enhance the oxidation even further [262]. Another plausible explanation for the 
increased phosphorylation of AMPK is that palmitate induce oxidative stress in 
endothelial cells [72], and oxidative stress per se has been shown to activate AMPK 
without strict AMP dependency [263, 264]. Interestingly, albeit not addressed in study 
II, recent reports on AMPK activation by GLP-1R activation have been published [152, 
265, 266], raising the possibility that AMPK signaling was also involved in the findings 
of study II.  
 
4.3 THE INVOLVEMENT OF eNOS AND ROS  
Given that FFAs impair endothelial function [252, 267] and reduce NO bioavailability 
[268], and that NO has been shown to protect from apoptosis [269, 270], the 
importance of eNOS and NO formation was investigated in both study II and III, 
although more in detail in study II. Both exendin-4 and metformin are known to 
induce NO formation in endothelial cells [149, 177]. In study II, palmitate was 
unexpectedly found to induce NO formation and treatment with exendin-4 was 
coupled to an even further enhanced NO production. Adding further credence to 
eNOS as a protector against lipoapoptosis, both pharmacological inhibition and 
genetic silencing of eNOS abrogated the lipoprotective effect of exendin-4, suggesting 
that the protective effect of exendin-4 is eNOS-dependent. In study II, we 
unexpectedly detected an increased phosphorylation of eNOS by palmitate exposure, 
which was lowered upon concomitant exendin-4 treatment, whereas -- in study III -- 
palmitate decreased phosphorylated eNOS levels, an effect that was reverted back to 
control levels by metformin. At a first glance this may seem a bit contradictory, but it 
might be due to the differential experimental conditions used. In study II, we 
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investigated the effect of palmitate under starvation conditions, while in study III cells 
were kept in 5 % serum throughout the experiment. In study II, we believe that the 
increased eNOS activation is due to uncoupling of the enzyme, causing it to produce 
superoxide instead of NO and therefore contributing to the increased ROS levels seen 
with palmitate incubation. When cells are under stress from starvation, their access to 
its substrate L-arginine is limited, which can lead to uncoupling [271]. Also, serum-
starvation per se induces ROS [272], which might cause an uncoupling of the enzyme 
due to oxidation of the cofactor BH4 [55]. In line with this, supplementation of BH4 in 
study II reduced both basal and palmitate-induced ROS production, to the same 
extent as exendin-4. On the other hand, the increased ROS production seen in study 
III, most likely does not originate from an uncoupled eNOS, but rather from a 
palmitate-induced NADPH oxidase activation [75], lipid oxidation or ceramide 
formation, all of which generate ROS [273]. Then again, this is purely speculative and 
has not been experimentally addressed, which is a limitation of study III. In study II, 
exendin-4 reduced FFA-induced ROS production and further increased NO production, 
by reducing the palmitate-induced eNOS phosphorylation, suggesting that exendin-4 
can partially reverse eNOS uncoupling. This may seem paradoxical, but it has been 
shown that peroxynitrate, formed when NO reacts with superoxide, inhibits Akt-
dependent Ser1177 phosphorylation of eNOS, but activates AMPK and increases AMPK 
dependent activation of the enzyme, which results in an increased superoxide 
production [264]. In study II, exendin-4 was able to increase Akt phosphorylation in 
the presence of palmitate, compared to palmitate alone. Adding to this, in study III we 
found that palmitate significantly increased AMPK phosphorylation. One can therefore 
speculate that exendin-4, in study II, partially restored eNOS uncoupling by increasing 
Akt-dependent eNOS phosphorylation [149], thus restoring the imbalance between 
NO and ROS generation. In study III, metformin was unable to reduce the increased 
ROS levels evoked by palmitate exposure, a somewhat surprising finding since others 
have shown that activation of AMPK reduces both FFA- and hyperglycemia-induced 
ROS formation in endothelial cells [152, 189]. However, as mentioned above, 
palmitate may increase lipid oxidation and ceramide formation, which both generate 
ROS [273]. Additionally, palmitate-induced lipid oxidation is even further increased 
upon simultaneous AMPK activation [262]. The unchanged ROS levels might therefore 
reflect an increased lipid oxidation, which contributes to metformin’s lipoprotective 
effect. Also, the fluorescent probe used in both study II and III is not ROS species 
specific and have been used by others to detect NO [274]. Since we improved eNOS 
dysfunction in both study II and III, albeit in different ways, an increased NO 
formation might therefore interfere with our assay, leading to an overestimation of 
ROS generation in cells co-incubated with palmitate and exendin-4 or metformin. But 
then again, this is speculative since NO formation was not measured in study III. 
 
4.4 THE MAPK PATHWAY IS INVOLVED IN MEDIATING FFA INDUCED APOPTOSIS 
Both study II and III investigated the involvement of the MAPK signaling pathway, and 
especially the two pro-apoptotic MAPKs, p38 MAPK and JNK. Both these kinases are 
stress-inducible and are activated upon noxious external stimuli such as, however not 
exclusively, ROS, hypoxia, ischemia and cytokines [275, 276]. Incubation with 
palmitate caused p38 MAPK and JNK phosphorylation in both study II and III, but co-
incubation with exendin-4 and metformin attenuated this activation; although 
metformin was not able to significantly reduce JNK phosphorylation, there was a clear 
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trend. p38 MAPK is suggested to be solely responsible for the increased apoptosis of 
HCAECs upon palmitate exposure [71]. This is contradictory to what we found in study 
II where we inhibited both p38 MAPK and JNK, and even then were we not able to 
completely prevent the lipid-induced apoptosis. In study III, upon inhibition of AMPK, 
metformin was no longer able to decrease the palmitate-induced p38 MAPK 
phosphorylation, suggesting that AMPK modulates mediators upstream of p38 MAPK. 
However, this unlikely occurs through reducing oxidative stress, which is a known 
inducer of p38 MAPK [275], as ROS levels were unchanged. Although blocking p38 and 
JNK led to a complete block of palmitate-induced ROS formation in study II, 
scavenging of ROS by the antioxidant Trolox® had no effect on apoptosis. This finding 
suggests, that in our experimental system ROS is not driving the lipoapoptosis, as been 
suggested by others [72]. We did not study the MAPK pathway upon inhibition of PKA, 
PI3K/Akt or eNOS, which of course is a limitation of study II, but in speculation, the 
PKA activator forskolin has been shown to inhibit p38 MAPK in HUVECs [277], and PKA 
activation has been shown to reduce JNK activation in cardiomyocytes [278], 
suggesting that exendin-4 may protect from lipoapoptosis by reducing p38 MAPK and 
JNK activation through PKA signaling pathways. As previously mentioned, GLP-1R 
activation can also induce AMPK phosphorylation [152, 266], suggesting that the 
AMPK pathway might be operative in modulating the activity of p38 MAPK and JNK 
also in study II.  
 
4.5 GLP-1R ACTIVATION SELECTIVELY TARGETS SMCs IN A RAT MODEL OF 
VASCULAR INJURY 
Restenosis after stent implantation has significantly decreased since the introduction 
of DES, but the use of DES is associated with an increased risk of late in-stent 
thrombosis due to a decreased re-endothelialization [279, 280]. This is caused by the 
non-selective anti-proliferative effect of the DES affecting all the cells in the vicinity, 
leading to impaired vessel healing and chronic inflammation, increasing  the risk of 
thrombotic events [281]. Based on previous findings from our group, where we 
reported that exendin-4 increases endothelial cell proliferation in vitro [149] and the 
results from study II, where we discovered that exendin-4 could protect from 
lipoapoptosis in vitro, our aim in study IV was to test whether these findings also were 
operative in vivo. Increasing the re-endothelialization process would be desirable since 
it could speed up the healing process of the vessel wall, thus decreasing the risk of 
thrombosis and restenosis. 
 
We used a non-diabetic rat model of vascular injury, where the endothelium is 
denuded causing a healing reaction in the vessel wall and the development of intimal 
hyperplasia [282]. We deliberately chose a non-diabetic rat model in order to evaluate 
if the effects exerted on the vessel were direct and not caused by glycemic and 
metabolic changes. Recently, there have been reports that exendin-4 can modulate 
intimal hyperplasia [157, 159] by reducing SMC proliferation [158]. Our findings are 
consistent with these reports; four weeks of treatment with exendin-4 in our injury 
model significantly decreased intimal hyperplasia and SMC proliferation formation in 
vivo, investigated both non-invasively with ultrasound and upon sacrifice with 
morphometric analysis and immunohistochemistry. We therefore set out to study the 
molecular pathways involved, mediating this effect. Our data show that the GLP-1R 
and subsequent cAMP/PKA signaling are both necessary for the reduced proliferation 
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of SMCs in vitro caused by exendin-4. This is in line with other research, showing that 
activation of cAMP/PKA can have differential effects in SMCs and endothelial cells 
[149, 283, 284]. PKA activation in SMCs led downstream to a decreased 
phosphorylation of ERK 1/2, whose activation is important for SMC proliferation [283], 
which is what we also detected in study IV. We also studied the effect of exendin-4 
treatment on eNOS phosphorylation, since eNOS is expressed in SMCs, NO is well 
known to inhibit SMC proliferation and migration [48], and exendin-4 has previously 
been demonstrated to increase phosphorylation of eNOS and to induce NO formation 
in endothelial cells [149]. We found that treatment with exendin-4 increased 
phosphorylation of eNOS at Ser1177 in SMCs, which is coupled to an increased activity 
of the enzyme and subsequent, NO formation [285, 286]. Further supporting the 
involvement of eNOS, pharmacological inhibition of eNOS almost completely blocked 
the anti-proliferative effect exerted by exendin-4. Also in line with our findings, NO 
donors have been shown to reduce ERK 1/2 activation and migration of SMCs [287]. In 
their entirety our findings suggests that exendin-4 reduces SMC proliferation in a PKA-
, eNOS- and NO-dependent manner.  
 
On the other side of proliferation there is apoptosis, and cell death might function as a 
counterbalance [288] to the increased proliferation of SMCs seen after vascular injury. 
Remarkably, and contrary to what we found in study II, exendin-4 increased apoptosis 
of SMCs in vitro in study IV. This pro-apoptotic effect seems to involve an increased 
phosphorylation and activity of p38 MAPK, as phosphorylation of p38 MAPK was 
blocked upon GLP-1R antagonism. This is directly opposite of what we reported in 
study II, where exendin-4 treatment decreased p38 MAPK activity in endothelial cells. 
On the other hand, there have been several reports of cAMP/PKA-dependent p38 
MAPK activation in many cell types, as thoroughly reviewed by Gertis et al [289], but 
also of PKA-dependent inhibition of p38 MAPK activation in HUVECs and a fibroblast 
cell line [277, 290], suggesting that cAMP/PKA signaling is cell type specific. The 
involvement of p38 MAPK in SMC apoptosis has previously been reported in both 
human SMCs [291] and airway SMCs [292]. The anti-proliferative and pro-apoptotic 
effect of exendin-4 might therefore work in concert to minimize the intimal 
hyperplasia, thus increasing lumen size and decrease the risk of restenosis.  
 
Interestingly, data from our ultrasound visualization in study IV show that treatment 
with exendin-4 significantly improved arterial wall elasticity of the damaged vessel. 
This effect was observed at an injured but re-endothelialized part of the artery, 
indicating that the re-grown endothelial cells might be better functioning compared to 
vehicle-treated animals. The clinical significance of this finding is that arterial wall 
elasticity is a very important determinant of blood pressure, both systolic and 
diastolic, in the elderly population. Hypertension in this group contributes to various 
cardiovascular complications such as stroke, heart failure and aneurysm rupture [293, 
294]. However, more research is needed to study the mechanisms behind this finding. 
 
Although our data from study II, and our group’s previously published study on 
proliferation of HCAECs [149] are promising, we were not able to detect any 
statistically significant stimulatory effect on vascular re-endothelialization by exendin-
4 in study IV. The reason for this discrepancy is still unresolved but might relate to 
timing. Four weeks might either be too early or too late to discern re-growth of the 
endothelial cells, or we may be using a suboptimal method to analyze the re-
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endothelialization process. Nevertheless and importantly, we demonstrate that 
exendin-4 treatment selectively targets the SMCs in vivo, since the endothelial cell 
regrowth after vascular injury was left intact. Such an effect is highly desirable, since, 
ideally, one wants to maintain a sustained inhibition of SMC proliferation, without 
suppression of endothelial cell coverage in healing a vascular wall injury. 
 
Another important aspect of our findings is that, although local delivery of the 
antiproliferative agents eluted by the DES minimizes systemic toxicity, it does not 
protect from drug-drug interactions with other anti-diabetic agents that are present in 
the circulation. It was recently reported that in a rabbit model of iliac artery stenting, 
simultaneous systemic treatment with metformin decreased endothelial coverage of 
stent struts of zotarolimus-eluting stents and bare metal stents as compared to the 
groups treated with zotaroliums-eluting stents or bare metal stents alone [96]. Our 
results from both study II and IV suggest that treatment with exendin-4 should not 
further impair the healing process in the vessel. This is an important finding since 
diabetic patients have an increased risk of late stent thrombosis  [92-95] and re-
intervention after angioplasty [90, 91], and more T2DM patients are today being 
treated with GLP-1-based therapies, making drug-drug interactions something that 
needs to be taken into consideration. Germane to this, it may be wise to compare the 
effects of GLP-1R agonists with those of insulin, since insulin (and high glucose) 
reportedly increases proliferation of SMCs [295-297]. In the setting of vascular 
remodeling and intimal hyperplasia formation after a vascular wall lesion or stent 
apposition, a stimulatory effect of insulin on SMC proliferation would be detrimental 
as it may promote restenosis. Supportive of this, it has been described, in a study 
systematically analyzing patients having undergone intravascular ultrasound, that 
diabetic subjects receiving insulin had smaller lumen dimension than subjects not 
treated with insulin, despite similar plaque burden, suggesting an impaired 
compensatory remodeling due to insulin treatment. However, it is unknown if it is 
merely a reflection of a longer standing and more severe diabetes or a direct effect of 
insulin on the vessel wall [82].  
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5 CONCLUDING REMARKS 
 
In conclusion, patients with T2DM have an increased risk of macrovascular 
complications, an increased atherosclerotic burden and an increased risk of 
complications after revascularization. Compared to microvascular complications, 
where the relationship to hyperglycemia is well supported, correcting solely 
hyperglycemia has so far not been successful in reducing cardiovascular events, 
highlighting the need for other strategies to improve the cardiovascular outcome for 
T2DM patients.    
 
In this thesis, we provide evidence that drugs used for the management of diabetes 
exert beneficial effects on the cells in the vasculature under both normal and 
simulated diabetic conditions. We show in study I that agents commonly used in the 
management of T2DM can stimulate proliferation of endothelial cells under normal 
and hyperglycemic conditions in vitro, which might contribute to a delayed 
development of atherosclerosis, by replacing dysfunctional endothelial cells with 
healthy ones. It may also contribute to maintaining the endothelial integrity by 
inducing a more rapid healing response upon endothelial cell injury or apoptosis, thus 
protecting the vessel wall from atherothrombotic events. It may also be beneficial for 
diabetic patients undergoing revascularization and treated with DES, by improving the 
re-endothelialization process thus decreasing the risk of late stent thrombosis and 
restenosis.  
 
Diabetic patients have been shown to have more circulating endothelial cells than 
healthy subjects, apparently independent of glycemia, indicating vascular injury. Since 
FFAs are elevated in T2DM patients, and FFAs impair endothelial function and lead to 
apoptosis of endothelial cells, we investigated whether commonly used anti-diabetic 
agents could protect HCAECs from lipoapoptosis. We also studied the molecular 
mechanisms underlying the protective effect of exendin-4 and metformin. We show in 
study I that a number of agents could lower FFA-induced caspase-3 activity and 
reduce apoptosis of HCAECs. In study II, we demonstrate that exendin-4 and GLP-1 
protect HCAECs against lipoapoptosis, an effect that is mediated through the GLP-1R 
involving PKA-, PI3K/Akt, eNOS-, p38 MAPK-, and JNK-dependent pathways. We also 
report that palmitate activates eNOS, stimulate NO release, increases ROS production 
by uncoupling of the enzyme, and that p38 MAPK and JNK signaling pathways are 
involved in palmitate-induced ROS production and lipoapoptosis. In study III, we 
evaluated the protective effect of metformin on lipoapoptosis found in study I. We 
found that metformin can protect HCAECs from FFA-induced apoptosis through an 
AMPK-dependent mechanism, which recovered eNOS activity and decreased p38 
MAPK signaling. 
 
We continued to explore the protective effect of exendin-4 found in vitro in study II in 
vivo in study IV. We analyzed the effect of exendin-4 on endothelial cells and SMCs in 
vivo, in a rat model of arterial injury and tried to elucidate the mechanisms of the 
effects seen in in vivo on SMCs in vitro. Our findings show that exendin-4 selectively 
reduces proliferation and increases apoptosis of SMCs, effects that require the GLP-
1R, PKA and eNOS. This selective effect of exendin-4, which is probably direct and not 
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mediated through glycemic effects, is therapeutically desirable as it minimizes 
neointima formation after vascular injury through inhibitory effects on SMCs, without 
impairing the re-endothelialization process. We also demonstrate that the arterial wall 
elasticity is improved, suggesting that even though we do not see an increased re-
endothelialization, the re-grown endothelial cells might become better functioning 
with exendin-4 treatment. 
 
To summarize, we show that drugs used in the clinical management of T2DM exert 
positive direct effects on the vasculature independently of their glycemic effects. This 
might be of clinical benefit for patients suffering from diabetes, and might serve to 
limit the adverse consequences of the macrovascular complications of T2DM, as 
dysfunction of endothelial cells is believed to contribute to premature development of 
atherosclerosis. Our findings might also be of therapeutic benefit for diabetic patients 
undergoing revascularization to treat atherosclerosis, since restenosis and late stent 
thrombosis are overrepresented and are potentially lethal complications among these 
patients. 
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6 FUTURE PERSPECTIVES 
 
Since study I was only a scanning study it would be of interest evaluate the underlying 
mechanisms regarding the increased proliferation and protection from apoptosis seen 
with the agents investigated. It would also be of interest to expand study III and 
further explore the lipoprotective effect of metformin, to further evaluate the 
importance of eNOS, NO and the MAPK signaling pathway and also address why we 
see differential effects in ROS production compared to other studies. Is it due to an 
increased fatty acid oxidation? Moving on from study IV, it would be interesting to 
further study the functionality of the re-grown endothelial cells. For obvious reasons it 
would be highly relevant to study the effect of GLP-1 analogues and DPP-4 inhibitors 
in a diabetic animal model, but also in another vascular injury model, i.e. in a vein graft 
model to simulate a clinical setting where patients undergo bypass surgery, which can 
be hampered by restenosis. Lastly, it would be very interesting to take our findings 
into the clinical setting to evaluate whether there is a vascular benefit for patients 
undergoing revascularization to be treated with incretin mimetics. 
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